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Abstract 
Non-viral gene delivery vectors are widely used for the delivery of genetic materials into 
mammalian cells. Currently, there is a need to develop cheap and efficient transfection 
agents for use in production of recombinant proteins, such as monoclonal antibodies, via 
transient gene expression (TGE). There are several barriers that non-viral vectors must 
overcome for successful transfection, such as cellular internalisation, escape of the 
endosome, protection and transportation of DNA through the cytosol, delivery of DNA into 
the nucleus, and finally be able to release the DNA to allow protein expression to occur. 
The ability to escape the endosome and gain entry to the nucleus are the two primary 
barriers to successful transfection. The processes involved in the pathways for cellular 
uptake, intracellular trafficking, and nuclear entry are still not fully understood. More 
detailed understanding of the pathways involved in transfection is needed in order to 
develop highly efficient transfection agents. 
 
This thesis investigates the use of three series of cationic diblock copolymers as 
transfection agents for the production of small and large recombinant proteins, as well as 
examining the pathways the polymers used to deliver the DNA into the nucleus. The 
diblock copolymers were synthesised using 'living' radical polymerization techniques, with 
each series using the same first block poly(2-dimethylaminoethyl acrylate) (PDMAEA). The 
second block consists of N-(3-(1H-imidazol-1-yl)propyl) acrylamide (ImPAA) or butyl 
acrylate (BA) or a combination of both. The copolymer with both ImPAA and BA units were 
used to mimic the influenza virus mechanism for endosomal escape. The three series of 
polymers were tested in both Chinese Hamster Ovary (CHOS) and Human Embryonic 
Kidney (HEK293) cell lines. Polymer A-C3, with the second block copolymer of the ImPAA 
and BA not only showed the best protection against DNase I  with a timed-release 
mechanism between 24-48 h, but also achieved the highest level of transfection efficiency 
in both cell lines tested. Using a GFP reported gene up to 50% of CHOS cells and 95% of 
HEK293 cells tested positive for gene expression. When transfections were performed in 
the presence of chloroquine, a chemical known to swell and burst endosomes, no increase 
in transfection efficiency was seen, suggesting that the polymer A-C3 is efficient at 
endosome escape.   
 
The A-C3 series was shown to be the most efficient at mediating transfection in both 
CHOS and HEK293 cells. Due to the high transfection efficiency of the A-C3 polymer in 
HEK293 cells, this polymer was thus chosen to investigate internalization and nuclear 
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entry pathways. Uptake of polymer/pDNA polyplexes was investigated through the use of 
specific inhibitors to block endocytosis pathways (chlorpromazine, filipin III, dynasore and 
amiloride). Our results indicate that the main endocytosis pathway used is clathrin-
mediated endocytosis. Nuclear entry was tested next. The pathway for plasmid DNA 
(pDNA), either complexed or alone, is thought to enter the nucleus either through the 
nuclear pores or during mitosis when the nuclear membrane is temporarily disintegrated. 
Through the use of wheat germ agglutinin that blocks nuclear pores it was demonstrated 
that entry occurs primarily though the nuclear pores, most likely via active transport due to 
the large size of pDNA. The relative pDNA copy number was determined for HEK293 cells 
transfected with A-C3 and PEI Max over a 48 h time period, and it was found that the 
amount of pDNA within the nucleus of cells transfected with A-C3 across all time points 
was higher than PEI Max, with the A-C3 polymer able to deliver 7 times the amount of 
pDNA than PEI Max. 
 
The production of a large recombinant protein was the final challenge for the three series 
of polymers. Monoclonal antibody (mAb) production was performed in both CHOS and 
HEK293 cell lines using optimum conditions for transfection, based on transfection using 
GFP as a reporter gene. Out of the polymers tested polymer A-C3 was once again the 
best performer, producing similar levels of mAb titre at day 4 to commercially available 
transfection agents PEI Max and Freestyle Max in HEK293 cells. However by day 8 the 
mAb titre for the A-C3 polymer was lower at 25mg/L compared to mAb titres of PEI Max 
and Freestyle Max which were both ~30 mg/L. This difference in titre is thought to be due 
to toxicity caused by the A-C3 polymer during transfection. 
 
The results presented in this thesis attempts to improve our understanding of the pathways 
involved in the successful delivery of pDNA, both inside the cell and the nucleus. The 
ability to rationally design cationic polymers for use as gene delivery vectors could result in 
the next generation of highly efficient transfection agents used in transient gene 
expression systems. 
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Chapter 1 – Introduction  
1.0 Introduction to the Biopharmaceutical Industry 
The biopharmaceutical industry has exploded since the 1980s when the first recombinant 
proteins produced were approved for clinical use. The annual worldwide revenue for 
biopharmaceuticals in 2012 was over US$165 billion with at least US$110 billion for 
recombinant antibodies and other proteins.1 The biopharmaceutical market includes the 
production of monoclonal antibodies (mAb), hormones, growth factors, fusion proteins, 
cytokines, therapeutic enzymes, blood factors, recombinant vaccines, anti-coagulants and 
nucleic acid-based products. The growth of biologic drugs in the US market has increased 
18.2% from 2011 to 2012 which was more than 3 times the growth seen from 2010 to 
2011.2 The production of biopharmaceuticals can occur in a variety of different hosts 
ranging from prokaryotic cells such as Escherichia coli (E. coli) to move complex systems 
such as transgenic animals and plants, insect cells and mammalian cell lines.3 Majority of 
biopharmaceutical products are either produced in mammalian cells or E. coli. From 2006 
to 2010 out of the 58 approved products, 32 were produced in mammalian cells and 17 in 
E. coli.4 Mammalian cells are the preferred host because they have the ability to correctly 
fold and assemble complex proteins as well as perform post-translational modifications, 
such as glycosylation, to produce recombinant proteins that are active and compatible in 
humans.3, 5 
 
Currently large-scale manufacture of recombinant proteins for human therapeutics is 
produced using stable cell line expression. There are several mammalian cell lines that 
have been used for the production of recombinant proteins including Chinese hamster 
ovary (CHO) Human Embryonic Kidney 293 (HEK293), Baby Hamster kidney (BHK21), 
human fibrosarcoma (HT1080) and mouse myeloma (NS0).5b, 6 CHO cells are the 
predominant cell line used for the industrial production of recombinant proteins as this cell 
line is well characterised, has the capacity to grow in suspension and recombinant proteins 
produced in this cell line have gained regulatory approval from agencies such as the 
FDA.3, 7 The production of stable cells lines has not changed significantly over the past 
three decades with either methotrexate (MTX) amplification technology or Lonza’s 
glutamine synthetase (GS) system used by biopharmaceutical companies to developed 
cell lines producing the gene of interest.8 In short, cells are transfected with an expression 
vector encoding both the gene of interest and a ‘selection’ gene. After transfection cells 
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undergo drug selection and cloning to determine which cells have successfully integrated 
both the gene of interest and the ‘selection’ gene. Cells with high recombinant protein tires 
are chosen for further characterisations such as growth and quality of recombinant protein 
before cell banking. This process of creating a stable cell line can take upwards of 6-12 
months, making it a time-extensive process as well as costly.6  
 
An alternative to stable cell line expression is transient gene expression (TGE). In TGE 
systems there is no need to identified and select cells that have integrated the gene of 
interest. This is one of the advantages of TGE as the production of protein of interest can 
occur within several weeks instead of months.9 Recombinant proteins expressed via TGE 
are of good quality and can be used for pre-clinical assessment, meaning that 
biopharmaceutical companies can speed up their ‘proof of principle’ stage by screening 
multiple potential therapeutic candidates in a relatively short time.6 This in turn cuts down 
on development costs, saving time and money. The disadvantage of TGE is that 
expression yields are typically lower at sub-gram quantities compared to stable cell line 
expression which typically yields gram quantities.6 Efforts have been made to increase 
production levels of TGE by optimizing host cell lines, vector systems, cell culture 
conditions and gene delivery reagents.10 The predominant cell lines used with TGE are 
CHO and HEK293.11 To date these two cell lines have produced the highest-yielding 
monoclonal antibodies titres at 2 g/L in CHOS-EBNA-GS and 1 g/L in HEK293-EBNA 
cells.10f, 12 A list of recent protein production titres can be found in Table 1-1. The 
successful delivery (or transfection) of the foreign DNA into the nucleus of mammalian 
cells is believed to be one of the key components to a high-producing TGE system. There 
are multiple different methods for the delivery of genetic material into mammalian cells 
(see section 1.1) with TGE systems typically using calcium phosphate13 or 
polyethylenimine (PEI)14 due to their relative ease of use.11, 15  
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Table 1-1: Examples of recombinant protein titres produced by transient gene expression 
in mammalian cells. 
Cell Line Yield Product Reference 
CHOS-EBNA-GS 2000 mg/L mAb 12 
HEK293-EBNA 1000 mg/L mAb 10f 
HEK293E 81 mg/L mAb 16 
HEK293E 50 mg/L Recombinant protein 17 
CHO DG44 300mg/L mAb 10a 
CHO DG44 90 mg/L mAb 18 
FreeStyle HEK 293-F 
FreeStyle CHO-S 
80 mg/L 
50 mg/L 
mAb 
mAb 
10b 
CHO-T 140 mg/L mAb 10e 
 
1.1 Overview of Delivery of Genetic Material into Mammalian Cells 
Since the 1960s techniques involving the introduction of genetic material into mammalian 
cells has diversified and improved significantly. The delivery of genetic material into cells 
can be used for a range of applications, including the study of gene function and 
regulation, production of recombinant proteins such as monoclonal antibodies, gene 
therapy and nucleic-acid vaccines. The introduced genetic material can be either DNA, 
linear or plasmid DNA (pDNA), or RNA, small interfering RNA (siRNA) or messenger RNA 
(mRNA).19 Delivery of the genetic material can be classified into two groups, viral or non-
viral vectors (Figure 1-1). Viral vectors generally have a higher transfection rate than non-
viral vectors but are limited by safety concerns such as toxicity, immune response and 
inflammatory response.20 Non-viral vectors are a safer alternative to viral vectors and offer 
more flexibility in terms of the size of the genetic material they can deliver. Non-viral 
vectors can be further classified into physical and chemical methods.  
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Figure 1-1: Different types of vectors used for the delivery of genetic material into cells. 
 
1.2 Viral Vectors 
Viral vectors can be divided into two groups depending on the mechanism they use to 
enter the cell. Enveloped viruses either fuse to the cell membrane or the endosomal 
membrane while non-enveloped viruses use specific virion proteins to either penetrate or 
disrupt the cell or endosomal membranes.21 No matter what method is used to enter the 
cell and escape the endosome, once in the cytosol the virus is transported to its normal 
site of replication, which is most commonly the nucleus. Apart from having high 
transfection efficiency, other advantages viral vectors have include their ability to protect 
the transgene by encapsulating it prior to and during internalisation. Also, many viruses 
have the tendency to block host cell protein production in favour of expression of the 
transgene.  
 
Since 1989, over 1900 gene therapy clinical trials have been approved with the majority of 
vectors being viral.22  There are a broad range of viral vectors available that can be used 
for either short-term expression (transient gene expression) or long-term expression 
(stable cell line) of the transgene. Adenoviruses give the most efficient gene transfer 
compared with other viral vectors, especially in vivo for a wide variety of cell types and are 
most suited to transient expression as they do not integrate into the host system.23 They 
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are able to transfer genes to both dividing and non-dividing cells. Retroviruses, unlike 
adenoviruses, integrate the transgene into the target cell chromosome.24 This typically 
leads to long-term expression of the transgene but at reduced levels. The major limitation 
of retroviruses is that transfection can only occur while cells are proliferating.23 Other 
viruses that have been investigated as possible transfection vectors include adeno-
associated virus, baculovirus, herpes simplex virus and lentivirus.25  
 
1.3 Non-Viral Vectors – Physical Methods 
Physical methods have been used to deliver genetic material into a range of different cell 
types both in vitro and in vivo. The delivery of the genetic material is facilitated by a 
physical force that causes transient holes or defects in the cell membrane to allow the 
entry of the genetic material either into the cytoplasm or in some cases the nucleus.  
Although high efficiencies can be achieved, a major disadvantage of these physical 
methods are that specific instruments are required to facilitate the transfection.26  
 
1.3.1 Electroporation 
Electroporation uses a short-pulsed electric field to alter the cell permeability, causing 
nanometre-sized pores to open in the cell membrane allowing the uptake of DNA from the 
surrounding medium. These pores can stay open to upwards of 30 minutes before they 
close with no noticeable adverse effects after the electric field has been discontinued.21 
This method was first used for gene transfer in mammalian cells in 198227 and in 1991 the 
first in vivo electroporation gene transfer was attempted.28 Although electroporation has 
been shown to work in a wide range of cell types from bacterial cells to mammalian cells to 
tissues such as skin and liver, it has its limitations such as the requirement of specialised 
equipment, as well as the need to use an increased number of cells and higher DNA 
concentrations compared to chemical methods.21   
 
1.3.2 Microinjection 
Microinjection is a procedure where genes are delivered directly into the cytoplasm or 
nucleus of a cell. This procedure is highly efficient but is time consuming as only a small 
number of cells can be treated at one time.21 By only transfecting single cells at a time, 
cellular processes, structure and function can be studied in vitro. This method is not suited 
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to large-scale in vivo or in vitro applications due to the time involved in this transfection 
method.29 
 
1.3.3 Particle Bombardment 
Particle bombardment was first described in 1987 for delivery of nucleic acids into plant 
cells.30 Since then this method has been used for delivering genetic material into 
mammalian cells. Particle bombardment can also be referred to as ballistic DNA transfer, 
or gene gun delivery, and the basic premise is that DNA or RNA is coated onto particles, 
usually consisting of gold, tungsten or silver that are non-toxic and then accelerated into 
the cytoplasm or nucleus of the cell via a highly pressurised gas. Unfortunately, the use of 
gene guns can cause considerable cell damage. That being said, gene guns are currently 
being investigated to deliver DNA into cells in the epidermis for DNA vaccine studies. 31  
 
1.4 Non-Viral Vectors – Chemical Methods 
Chemical methods use synthetic delivery vehicles to bind to genetic material to form 
complexes. These complexes are then able to protect the genetic material and facilitate 
intracellular delivery via endocytosis. Once inside the cell, the complexes are released into 
the cytosol and the genetic material is transported to the nucleus where expression can 
take place. This process sounds relatively easy, but chemical methods have many barriers 
to overcome. Over the years a wide range of synthetic delivery vehicles have been 
studied. Each mode of transfection works in slightly different manner, thus leading to 
significant variability in the rate of transfection. 
 
1.4.1 Calcium Phosphate 
Transfection using calcium phosphate was developed in 1973 by Graham and Van der 
Eb.32 The method is relatively inexpensive and simple; firstly the DNA is mixed with 
calcium chloride solution before a phosphate solution is added to form CaPi/DNA 
precipitates. These precipitates can be absorbed onto the cell surface and are internalised 
by endocytosis.33 CaPi/DNA precipitates are able to work in a number of cell types but the 
efficiency and reproducibility is low. The formation of CaPi precipitates relies on several 
key parameters such as pH, temperature and serum to name a few.34 Several groups have 
worked on improving this method by optimizing key parameters such as method of CaPi 
preparation, exposure time to CaPi/DNA precipitates and post-transfection treatments 
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such as glycerol or chloroquine.13, 35 Drawbacks to this method include the time-consuming 
process of forming the precipitates (especially for large-scale transfection) and the need 
for serum in the transfection medium, especially when the overall trend in industry is to 
move towards more defined growth conditions. 
 
1.4.2 Cationic Liposomes 
The technique involving lipids as non-viral vectors for DNA delivery started to emerge in 
the late 1970s / early 1980s.36 The first stable cationic lipid for DNA delivery was described 
by Felgner in 1987.37 Since then, hundreds of lipids have been developed and tested for 
their ability to deliver genetic material into cells. All generally share a common structure 
consisting of a cationic hydrophilic head and a hydrophobic tail that is joined by a linker 
structure.38 The most commonly used head groups consist of primary to quaternary amine 
groups and the hydrophobic tail usually made of two types of hydrophobic moieties, either 
two hydrocarbon chains or cholesterol. The linker between the cationic hydrophilic head 
and hydrophobic tail can be ether, ester, carbamate or amide bonds. 39 A list of commonly 
used cationic lipids used for the delivery of genetic material can be found in Table 1-2. 
When mixed, cationic liposomes and anionic DNA form compact structures called 
lipoplexes. It is believed that the positively charged head group interacts with the 
negatively charged backbone of DNA through electrostatic interactions.40 Also, due to the 
overall net positive charge of the lipoplex, it may facilitate cellular uptake by binding to the 
negatively charged cell membrane. The efficiency of the cationic liposomes can be 
influenced by several different factors such as the chemical structure of the cationic lipid, 
the resulting size and structure of the lipoplex, the charge ratio between the cationic lipid 
and the DNA, and the total amount of lipoplex added to the cells, as well as the cell type. 41 
Cationic liposomes are able to achieve high transfection efficiencies but one drawback is 
that the lipids are usually difficult to produce in the laboratory and can be expensive to 
purchase from commercial sources.  
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Table 1-2: Examples of lipids used in the delivery of genetic material. 
Lipid Abbreviation 
1,2-Dioleoyl-sn-glycero-3-phosphatidycholine DOPC 
1,2-Dioeoyl-sn-glycero-3-phosphatidylethanolamine DOPE 
N-[1-(2,3-Dioleyloxy)propyl]N,N,N-trimethylammonium 
chloride 
DOTMA 
1,2-Dioleoyloxy-3-trimethylammonium-propane DOTAP 
3β-[N-(N’,N’-Dimethylaminoethane)-carbamoyl]cholesterol DC-Chol 
Freestyle Max   
Lipofectamine 2000  
 
 
1.4.3 Cationic Polymers 
Cationic polymers have also been used to deliver genetic material into cells and can be 
classified as either naturally occurring or synthetic. Similar to cationic liposomes, cationic 
polymers interact with the DNA through electrostatic interactions. The resulting complex is 
referred to as a polyplex. Also similar to lipoplexes, the uptake of the polyplexes into the 
cell is thought to occur by interactions between the negatively charged cell surface and the 
positively charged polyplex via endocytosis.42 One of the first cationic polymers to be used 
as a transfection reagent was Polybrene, but due to its effectiveness only in certain cell 
lines this polymer did not gain widespread use.21 Since then, a large number of cationic 
polymers have been investigated and it was found that their transfection efficiency and 
cellular toxicity differ greatly. Several cationic polymers investigated include chitosan-
based vectors43, polyethylenimine (PEI)14, poly(amino) acids44, poly(dimethylamino ethyl 
methacrylate)45 and Poly(L-lysine)46. 
 
One of the most investigated polymers since being reported in 1995 as a gene-delivery 
vehicle is PEI.14a, 47 It has been reported that PEI has the ability to transfect a wide variety 
of cell lines.48 It is believed that its effectiveness across multiple cell lines is due to its 
buffering properties. The structure of PEI can be either branched or linear and consists of 
primary, secondary and tertiary amines which have the potential to be protonated.14b The 
non-protonated amines are what gives PEI its buffering properties and its ability to escape 
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the endosomes before degradation of the DNA can occur via the proton sponge effect 
(discussed further in the next section).49  Even though PEI is able to achieve high 
transfection efficiencies, one if its drawbacks is toxicity at high concentrations. It is known 
that transfection efficiency and toxicity of PEI is related to its structure, molecular weight 
and charge of the polymer.50 A study by Fischer et al 1999 has shown that branched PEI 
at a low molecular weight of 10 kDa is efficient at transfection and is less toxic than a 
commercial high molecular weight PEI.51 The same study showed that lower molecular 
weight PEI (2 kDa) was found to be relatively non-toxic but also unable to achieve the 
same level of transfection efficiency. Strategies to reduce the toxicity of PEI but keep the 
same level of efficiency have included cross-linking low molecular weight PEI using 
biodegradable disulphide linkages or inert polymers.52 
 
1.5 Barriers to Successful Transfection for Cationic Polymers 
Regardless of the delivery method, the primary goal is to achieve a high level of 
transfection efficiency with minimal cell toxicity.  For transfection to be successful it must 
be able to overcome certain barriers both within and outside the cell. (Reviews 53) Outlined 
in Figure 1-2 are the barriers that need to be overcome for a successful transfection. The 
first in the series of barriers that needs to be overcome is that the cationic polymer must be 
able to bind and condense the negatively charged DNA to a size that is able to enter the 
cell. The resulting polyplex is then able to bind to the negatively charged cell membrane 
and internalise via the endocytosis pathways. Escape of the endosome is considered to be 
one of the major barriers to a successful transfection. If the polyplex is unable to escape 
the endosome, then degradation of the DNA may occur or actively transported back 
outside the cell. Once the polyplex has escaped the endosome and is released into the 
cytosol, competitive binding of intracellular proteins and subsequent DNA degradation can 
also become an issue. Ideally, the cationic polymer must be able to protect the DNA until it 
is trafficked to the nucleus. This is the next major barrier to successful transfection: nuclear 
entry. Entry of the DNA into the nucleus is thought to occur either still complexed to the 
polymer or as naked DNA. It is believed that disassociation between the polymer and DNA 
must occur prior to expression of the transgene. 
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Figure 1-2: Barriers involved in DNA delivery for successful transfection. (A) Complexing 
of DNA and polymer. (B) Transport across the cell membrane via endocytosis. (C) Escape 
the endosome pathway. (D) If complex cannot escape the endosome then degradation 
occurs in the lysosome. (E) Disassociation of polyplex.  (F) Transport through the cytosol 
and entry into the nucleus. (G) Expression of the gene. 
 
1.5.1 Packaging and Protection of DNA 
For a cationic polymer to be an effective gene delivery vehicle it must be able to package 
and protect the DNA. The cationic polymer packages the DNA through electrostatic 
interactions between the positively charged groups on the polymer and the negatively 
charged phosphates along the DNA backbone. This is a spontaneous process and occurs 
when the cationic polymer and DNA are mixed.53a The resulting polyplex not only provides 
protection to the DNA against degradation by nucleases found within the cell54, but also 
prevents repulsion between the negatively charged DNA and the negatively charged cell 
membrane facilitating entry into the cell. 
 
1.5.2 Intracellular Barriers 
Entry of substances into the cell is regulated by the cell membrane and this first biological 
barrier that the polyplex must overcome. The positively charged polyplex is thought to 
interact with the negatively charged proteoglycans on the cell surface55 and then becomes 
internalised by endocytosis. Endocytosis has been generally accepted as the main 
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mechanism of internalisation of non-viral vectors such as cationic polymers.56 There are 
several different endosomal pathways and they are usually divided into two groups: 
phagocytosis and pinocytosis. The latter can be further divided into three types: clathrin-
mediated endocytosis, caveolae-mediated endocytosis and macropinocytosis57. There 
have been numerous studies investigating which pathways cationic polymers utilised but 
the results have been divided.  For example von Gersdorff et al 2006 reported that for 
successfully transfection the internalization pathway is dependent on both cell type and 
polyplex type.58 and Rejman et al 2005 reported for uptake of PEI polyplexes that 
internalisation is by both clathrin-mediated and by caveolae-mediated endocytosis with 
only the later one resulting in efficient transfection.59 
 
1.5.3 Escape 
Once the polyplex has gained entry into the cell via endocytosis there are many possible 
pathways available to the polyplex; these include degradation, recycling back to the cell 
surface, sorting to acidic and degradation vesicles (lysosomes) or delivery to an 
intracellular organelle (Golgi apparatus or endoplasmic reticulum).60 It is believed that 
cationic polymers are trafficked into the late endosomes where there is a an influx of 
protons by the ATPase proton-pump causing the vesicle to rapidly acidify to pH 5-6.53a 
Release from the endosome is critical before the polyplex is then trafficked to the 
lysosome where there is a further drop in pH and may lead to degradation by the 
lysosomal hydrolytic enzymes.61  To overcome the barrier of endosomal escape some 
polymers have been designed to utilise the influx of protons through the use of pH-
responsive moieties. The most commonly used are protonable amino groups such as 
secondary and tertiary amines and imadazoles.62 As the endosome acidifies it is thought 
that the amino groups on the polymer become protonated, causing more of an influx of 
protons resulting in the vesicle to osmotically swell, rupture and release the polyplex into 
the cytosol. This mechanism is referred to as the “proton sponge” effect (Figure 1-3).49 
Other techniques that have been employed to help polyplexes escape the endosome are 
the use of endosomal release peptides and alkylated carboxylic acids.  Endosomal release 
peptides undergo a structural change due to a change in pH. At neutral pH the structure is 
a random coil but as the endocytic vesicle acidifies a conformation change is triggered 
resulting in formation of an α-helical conformation which is believed to fuse to the 
endosomal membrane. This interaction can lead to pore formation, induction of membrane 
fusion and/or lysis of the endosomal vesicle.63 Alkylated carboxylic acids work in a similar 
way to endosomal release peptides as they are designed to incorporate the same 
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functional groups (alkyl and carboxyl) that are believed to be responsible for the 
membrane disruption properties.62 
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Figure 1-3: The ‘proton sponge’ effect. As the endosome acidifies through the influx of 
protons by the ATPase proton-pump (red), the polymer (yellow) becomes protonated 
resulting in a further influx of protons and water. Osmotic pressure increases, causes the 
endosome to swell, rupture and release the polymer into the cytosol.  
 
1.5.4 Nuclear Entry and Disassociation 
The last two critical steps for a successful transfection are entry into the nucleus and 
disassociation between the polymer and DNA, although not necessarily in that order. The 
nucleus is surrounded by a double membrane called the nuclear envelope (NE) which 
separates the genetic material from the cytoplasm. Throughout the NE are nuclear pore 
complexes (NPC) which are highly selective and bidirectional transport channels. Several 
imaging techniques such as cryo-electron tomography have been used to visualise the 
structure of the NPC.64 The NPC is considered a tripartite structure with a central domain, 
and cytoplasmic and nuclear regions. The cytoplasmic region consists of eight 
approximately 50 nm cytoplasm filaments and ring moiety. The nuclear region consists of 
eight 75 nm rods inclined towards a distal ring plus an additional eight intranuclear 
filaments. Connecting the cytoplasmic and nuclear regions is the central channel which is 
approximately 90 nm in length. The channel is hour-glass in shape with the diameter in the 
middle 45-50 nm and expands to 70 nm at its edges.65 The NPC are made up of 
approximately 50 different types of proteins called nucleoporins (nups).66 One third of 
these nups contain phenylalanine and glycine repeats (FG-nups) which are hydrophobic 
and are believed to play a key part in the transport of cargo through the NPC.67   
 
Transport of DNA or polyplex across the NPC can be either passive or active with size 
playing a large part. Small payloads such as small proteins less than 40 kDa with a 
diameter less than 9 nm are able to passively enter the nucleus while larger payloads up 
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to 39 nm require active transport.68 Active transport requires specific targeting signals 
known as nuclear localization signals (NLS), which recognise nuclear import transporters 
such as karyopherin. Such complexes are then able to pass through the NPC by 
hydrophobic interactions with the FG-nup.68d, 69 The direction of the transport across the 
NPC is mediated by a small GTP-binding protein, RAN.70 The exact mechanism of 
transport though the NPC is not known but there are several models proposed such as the 
affinity gradient model, Brownian affinity model and selective phase model.65b, 71 
 
It is believed that due to the size of DNA either linear or circular, passive entry into the 
nucleus via the NPC is unlikely. Therefore, two mechanisms have been suggested to 
explain how pDNA is able to enter the nucleus. The first is during mitosis when the nuclear 
membrane is temporarily disintegrated allowing for the uptake of pDNA into the nucleus; 
and the second is though active transport of the DNA though nuclear pores. 40 In an 
attempt to improve nuclear entry of pDNA, various strategies have been employed such as 
coupling pDNA and/or polymer to NLS peptides or by including DNA nuclear Targeting 
Sequences within the pDNA. 72  
 
Disassociation between the polymer and pDNA is assumed necessary to occur for 
transcription to take place.73 To avoid degradation of the DNA within the cytosol, it is 
presumably best for disassociation to occur near or within the nucleus. Techniques behind 
disassociation include incorporating thermoresponsive properties or hydrolytically 
degradable or reducible linkages within the polymer such as disulphide or ester bonds.62  
 
1.6 Techniques used to Investigate Transfection Mechanisms – Cellular Uptake 
and Nuclear Entry 
Numerous groups have used chemical inhibitors to study the endocytosis pathways 
involved in the uptake of non-viral vectors within cells as well as pathways involved in 
nuclear entry. Table 1-3 lists some of the chemical inhibitors used, targeted pathways and 
mechanism of inhibition. 42a, 59, 74  
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Table 1-3: Chemical inhibitors used to study mechanisms within the cell.42a, 74d, 74f, 74g 
Pathway Agent Mechanism 
General inhibitor of 
endocytosis 
Low temperature 4°C Energy depletion 
Dynasore Inhibitor of dynamin function 
Clathrin-mediated 
endocytosis 
Chlorpromazine Disassociation of clathrin lattice 
Potassium depletion Disassociation of clathrin lattice 
Caveolae-mediated 
endocytosis 
Filipin III Cholesterol binding 
Genistein Tyrosine kinase inhibitor 
Macropinocytosis 
Amiloride Inhibits the Na+/H+ exchange protein 
Phorbol esters Protein kinase C activators 
Acidification of 
endosome 
Chloroquine Increases endosomal pH 
Bafilomycin Blocks v(H+)ATPase 
Nuclear Pore 
Complex 
Wheat germ agglutinin Binds to N-Acetylglucosamine moieties  
Anti-FG repeat 
antibodies 
Blocks importins from docking to NPC 
 
1.7 Methods for Producing Cationic Polymers used in Transfection 
Cells are highly complex and have several natural barriers to stop foreign substances from 
entering as described in section 1.5. The ability to build and control the formation of 
nanoparticle polymers is essential in producing a complex polymer that is able to deliver 
genetic material into a highly complex cell. ‘Living’ radical polymerization (LRP), including 
techniques such as single electron transfer-living radical polymerization (SET-LRP) and 
reversible addition-fragmentation chain transfer polymerization (RAFT) have been shown 
to be able to produce complex polymers. These techniques are able to control certain 
attributes of the polymer such as functionalities, architecture and molecular weight.  
 
1.7.1 Single Electron Transfer-Living Radical Polymerization  
SET-LRP is a ‘living’ radical polymerization technique used for producing polymers for 
therapeutic applications and was first reported in 2002.75 One of the advantages of this 
method is the ultra-fast synthesis of high molecular weight polymers at room temperature 
or below.76 The key step is the generation of CuO and CuX2/L required for the reversible 
termination step. This technique has been used to generate a wide range of different 
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architectural polymers such as star block-copolymers, block copolymers and other tailored 
polymers.77 
 
1.7.2 Reversible Addition-Fragmentation Chain Transfer Polymerization 
RAFT polymerization is a versatile process that can occur under a range of different 
conditions. Polymers are synthesized by RAFT using chain transfer reagents that contain 
thiocarbonylthiol moieties. The rapid interexchange between the active propagating 
radicals and the dormant intermediate provides equal chance for all chains to grow and 
results in a narrow polydispersity of the polymers.78 The have been numerous polymers 
produced via RAFT polymerization for the use in therapeutic applications such as the 
delivery of genetic materials.79  
 
1.8 Project Aims 
Currently there is knowledge void in the area of transient transfection of non-viral vectors. 
This current void relates to the lack of understanding of the mechanisms in TGE as well as 
the intracellular trafficking of the DNA once inside the cell. The main aim of this work is to 
use purposely-built cationic polymers to investigate pathways involved in cellular uptake 
(endocytosis) and delivery of the DNA into the nucleus. The ability of these purpose-built 
cationic polymers to be used as an alternative transfection agent in industrially relevant 
mammalian TGE systems was also investigated.  
 
Chapter 2 describes the ability of the novel polymers to transfect mammalian cells using 
pDNA. PDMAEA is able to self-degrade through a self-catalysed hydrolysis mechanism 
independent of environment conditions. The timed-release ability of PDMAEA in 
combination with a variety of block copolymers was investigated to determine if release of 
pDNA from the polymer close to time of mitosis will result in high transfection efficiency 
and increased recombinant protein production. To determine if the novel polymers are able 
to overcome the many barriers within and without the cell, physical and biological 
properties of the polymer/pDNA complexes were examined. These properties include 
binding, size, zeta potential and release between the polymer and pDNA. The polymers 
ability to escape the endosome and facilitate pDNA entry into the nucleus was also 
monitored with successful transfection determined through the expression of a fluorescent 
protein (GFP) in HEK293 cells. 
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Chapter 3 investigates the pathways involved in cellular uptake (endocytosis) and delivery 
of the pDNA into the nucleus of mammalian cells with a focus on the A-C series polymers 
as the transfection agents. Endocytosis is generally accepted as the main entry pathway 
into the cell with several endocytosis pathways available. To determine which pathway the 
polymers utilised transfections were performed in cells pre-treated with chemical inhibitors 
that block specific endocytic pathways. Nuclear entry was also investigated as this is 
considered one of the major bottlenecks for successfully transfection. Two different 
pathways have been proposed for nuclear entry, the first is during mitosis and the second 
is through the nuclear pores. To investigate which pathway pDNA is delivered into the 
nucleus, cells in the exponential growth phase were pre-treated with a nuclear pore 
inhibitor before transfection and nuclear uptake was determined by the expression of GFP 
in HEK293 cells. 
 
Chapter 4 investigates the transfection ability of the three series of novel polymers in two 
different parental cell lines, CHOS and HEK293, for the production of two different 
recombinant proteins, a fluorescent protein and a monoclonal antibody. Successful 
transfection of the three novel polymer series in CHOS cell was determined by expression 
of GFP. Two different approaches to monoclonal antibody production were compared in 
HEK293 using polymer A-C3 as transfection agent to determine which approach was 
superior. Finally, a transient gene expression study using the superior approach for 
monoclonal antibody production was performed using all three polymer series and 
monoclonal antibody titres were determined over 8 days. 
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Chapter 2 – Timed-Release Polymers as Novel Transfection Reagents 
2.1 Abstract 
Development of novel agents that mediate nucleic acid delivery into cells has 
widespread application from basic cell biology to gene therapy. Enabling 
subsequent gene expression relies on the efficient delivery of DNA into the 
nucleus. In this work, we have developed a series of polymers designed to release 
DNA, via a self-catalysed hydrolysis mechanism, in a time-dependent manner to 
test if release of DNA near the time of cell division (which typically occurs every 24 
h in mammalian cells) would result in an increase in levels of gene expression. We 
utilized a transient gene expression system to test our delivery potential. Our 
results show that the polymers are able to bind to DNA for up to 24 h and in some 
cases 48 h before release, thus providing sufficient time for endosomal escape and 
transport to the nucleus. Polymer A-C3, which bound DNA for up to 48 h, was able 
to achieve the highest levels of transfection efficiency. Using a GFP reporter gene, 
up to 95% of cells were positive for gene expression, which was much greater than 
the commercially available Freestyle Max. This work demonstrates a link between 
protection of DNA against degradation and high levels of transfection, indicating 
that protection of DNA is also a limiting factor in successful transfection. We 
postulate that due to the strong binding of the polymers to the DNA and the large 
size of the polyplexes, which are significantly larger than the nuclear pores, entry 
into the nucleus occurs through passive transport during cell division and nuclear 
envelope breakdown.  
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2.2 Introduction 
Over the past couple of decades there has been considerable work on the delivery 
of genetic material into mammalian cells for a wide range of applications, ranging 
from basic cell biology to recombinant protein production to gene therapy. The 
production of recombinant proteins usually occurs via stable cell line expression 
which can take several months (usually 6-12).1 An alternative method is transient 
gene expression, which can take only weeks to produce a target protein,2 the 
system used in this study. The delivery of genetic material can occur through 
physical, chemical or biological methods. Physical methods include techniques such 
as electroporation or microinjection, chemical methods use synthetic transfection 
reagents such as calcium phosphate, cationic liposomes and cationic polymers, and 
biological methods use viral vectors, to transport the genetic material across the cell 
membrane.3 Due to safety concerns, cationic polymers and liposomes are preferred 
over viral vectors for use as transfection reagents. A variety of different cationic 
polymers and liposomes have been studied including chitosan-based vectors4, 
polyethylenimine (PEI)5, poly(amino) acids (PAA)6, poly(dimethylamino ethyl 
methacrylate)7, Poly(L-lysine)8 and N-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTMA).9 
 
For a transfection reagent to be effective in the delivery of genetic materials into 
mammalian cells, it must have certain characteristics which include the ability to 
bind and protect the DNA from nuclease degradation, be rapidly taken-up by cells, 
escape the endosome and then deliver the DNA by itself or as a complex across the 
nuclear membrane.10 Since 1995 when PEI was first discovered by Boussif et al., it 
has been intensively studied for the above characteristics and its ability as a 
transfection reagent.5a, 11 PEI is able to efficiently bind and condense plasmid DNA 
(pDNA) to form PEI/pDNA polyplexes that favourably interact with the negatively 
charged cell-surface heparin sulphate proteoglycans to facilitate cellular uptake via 
endocytosis.12 The polyplexes are then trafficked into acidic endosomes where 
escape into the cytosol occurs via the buffering capacity of the various amine side 
groups on PEI (denoted as the proton sponge effect).13 The polyplex must then 
deliver the DNA to the nucleus where transcription of the DNA can take place. The 
mechanism for nucleus translocation using PEI as the transfection reagent is not 
fully understood. It has been proposed that cellular division is required,14 which 
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contradicts the observation of PEI within the nucleus of non-dividing cells.15 Despite 
the fact that PEI has been reported to achieve high transfection efficiencies using a 
wide variety of cells and works in a wide range of conditions and is relatively cheap 
compared to proprietary compounds such as Lipofectamine and Freestyle Max 
(both lipid-based transfection reagents), which are also very widely used, it also has 
several disadvantages including structural variation, polydispersity and even high 
levels of toxicity.16 Therefore, the ideal transfection reagent should include the 
above mention characteristics as well as be homogeneous with no batch to batch 
variations (i.e. consistent defined structure) and be non-toxic to cells, possibly by 
being able to degrade into benign non-toxic by-products that can be expelled from 
the cell.  
 
After endosome escape, the protection and transportation of the DNA into the 
nucleus are considered to be the next major bottlenecks for successful transfection. 
It has been reported that the half-life of pDNA within HeLa cells is estimated to be 1-
2 h.17 The two main mechanisms proposed for nuclear entry are either  passive 
entry when the nuclear membrane is temporarily disintegrated during cell division, 
or by active transport through the highly regulated nuclear pores (approximately 25 
nm).18 Therefore it would be highly advantageous for the transfection reagent to be 
able to either cross the nucleus membrane still bound to the DNA, or to have a 
timed-release characteristic that bound the DNA, and therefore providing maximum 
protection, until time of cell division, which in mammalian cells is generally every 24 
h (see Scheme 2-1B). 
 
In this study, we used a novel polymer, poly(2-dimethylaminoethyl acrylate) 
(PDMAEA, pKa ~ 7.1), in combination with other polymers as shown in Scheme 2-
1A made by single electron transfer-living radical polymerization (SET-LRP)19 to 
deliver pDNA to HEK293 cells, and study the transfection efficiency through GFP 
production. This polymer self-degrades through a self-catalysed hydrolysis 
mechanism to a negatively charge and nontoxic poly(acrylic acid) in a time-
dependent manner (i.e. from a cationic to anionic polymer), in which degradation is 
independent of both the molecular weight of the polymer and pH of the 
environment,20 allowing a predictable release time of negatively charged 
biomolecules regardless of cellular environment. PDMAEA has recently been 
incorporated as part of block copolymers for the self-assembly of timed-release 
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nanoparticles.21 This polymer has also been shown to bind strongly to and release 
siRNA at a defined time (~17 h), independent of the environmental conditions.22 The 
advantage of this polymer is its ability to release where external or environmental 
triggers are not accessible or can be variable. The resultant polymer after 
degradation is non-toxic, thus avoiding problems of toxic accumulation. In the case 
of siRNA delivery, the inclusion of PDMAEA in the block copolymer resulted in down 
regulation of the polo-like kinase 1 pathway, an in vitro model for the bone cancer 
osteosarcoma, and complete cell death.23 Here, our aim was to use the time-
release characteristic of PDMAEA incorporate into a variety of block copolymers to 
study the binding and release of pDNA. We further wanted to determine, due to the 
release time of 17-24 h of PDMAEA, whether protecting and then releasing pDNA at 
mitosis (see Scheme 2-1B) will result in increased levels of transfection efficiency 
and recombinant protein yield. 
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Scheme 2-1: (A) Chemical structures and number of repeating units of P(DMAEA) 
(A), P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-
C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-D1, A-D2 and A-D3). (B) 
Proposed mechanism for nucleus entry of polymer/pDNA complexes during mitosis. 
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2.3 Methods and Materials 
2.3.1 Synthesis of Novel Nanoparticle Polymers 
Information regarding the synthesis of P(DMAEA), P(DMAEA-b-ImPAA) (A-B1, A-
B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and 
P(DMAEA-b-(DMA-co-BA)) (A-D1, A-D2 and A-D3) polymers can be found in the 
reference.23a  
 
2.3.2 Size and Zeta Potential Measurements 
Dynamic light scattering (DLS) experiments were performed using a Zetasizer 
3000HS (Malvern). The Z-average diameter was measured five times for each 
sample and zeta potential three times. pDNA (16 µg) was mixed with polymers at 
different N/P ratios (5-50) in a total volume of 2 mL, vortex and left to complex at 
room temperature for 30 min before measurement.  
 
2.3.3 Agarose Gel DNA Retardation Assays 
The binding capabilities of the polymers to pDNA were assessed using 
electrophoresis. pDNA (1 µg) was mixed with polymers at different N/P ratios (0.5-
20) vortex, and left to complex at room temperature for 30 min. The resulting 
polyplexes were mixed with 2 µL DNA loading dye before loading onto a 1% 
agarose gel stained with SYBR Safe (Life Technologies). Gels were run at 90 V for 
30 min before visualised using ChemiDoc MP (BioRad). 
 
2.3.4 DNase I Protection Assays 
The ability of the nanoparticle polymers to protect the pDNA against nuclease was 
examined using DNase I. Polyplexes were prepared the same as DNA retardation 
assays but were treated with 1 µL of DNase I (1000 units/mL in a buffer containing 
100 mM Tris, 25 mM MgCl2 and 5 mM CaCl2) and incubated at different time 
intervals, 30 or 120 minutes. After incubation 5 µL of 100 mM EDTA was added and 
incubated for a further 10 min at 75 °C to inactivate DNase I. The mixture was 
further incubated for 2 h with 10 µL of heparin (5 mg/mL) to dissociate the 
polyplexes. Samples were run on a 1% agarose gel stained with SYBR Safe (Life 
Technologies) at 90 V for 30 min. The released pDNA was visualised using 
ChemiDoc MP (BioRad). 
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2.3.5 Transfection Studies 
Cell density day of transfection for HEK293 cells was 2x106 cells/mL. Polyplexes 
were prepared in sterile water (25% of the initial culture volume) at different N/P 
ratios (5-30) using 2 µg DNA (pEGFP) per millilitre of culture. Polyplexes were 
vortex for 30 s and left at RT for 30 min before addition to the cells. Freestyle Max 
(Life Technologies) was prepared according to the manufactures protocols except 
cell culture volume was 2 mL. Transfected cultures were incubated at 37 °C in a 
humidified 7.5% CO2 atmosphere on an orbital shaker at 140 rpm until 4 h post-
transfection where cultures were fed with an equal volume of Freestyle 293 
supplemented with 0.4% ACA (v/v) (Life Technologies). The cultures were then 
incubated at 37 °C. For endosomal escape assays cells were pre-incubated with a 
final concentration of 100 µM chloroquine 1 h before transfection. Chloroquine 
remained present for the entire experiment. Transfection efficiency was measured 
48 h post-transfection via the FACSAria II (BD, San Jose, CA). Ten thousand 
events were measured per sample. Cell density and viability were measured using 
an automated trypan blue exclusion assaying using the Cedex HiRes Cell Counter 
(Innovatis AG, Bielefield, Germany).   
 
2.3.6 Trafficking Experiments 
HEK293 cells were prepared as above. Polyplexes were prepared in the usual way 
except the pDNA was labelled with Cy5 using the Label-IT kit (Mirus Bio, Madison 
WI). At 4 h post-transfection wells were washed with PBS and then with 0.5 M 
Glycine pH2.2 in PBS. Cells were then fixed with 4% (w/v) paraformaldehyde in 
PBS for 20 min at RT followed by 3 x 1 min washes with PBS. Cells were mounted 
on glass sides with VECTASHIELD HardSet Mounting Medium with DAPI (Vector 
Laboratories) and coverslip place over top. Slides were left overnight at 4 °C and 
visualised under confocal microscope LSM 710 (ZEISS, Goettingen, Germany). 
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2.4 Results and discussion 
2.4.1 Polymer/DNA Binding 
The homopolymer PDMAEA and three sets of diblock copolymers, with PDMAEA 
being the first block, were prepared by SET-LRP. The second block for each series 
was either ImPAA, BA, or a combination of both.23a In each series, the number of 
monomer units was kept constant, and the number of monomer units of the second 
block were increased (see Scheme 2-1A). 
 
For the polymers to be successful transfection reagents, they must have the ability 
to bind and condense pDNA, as well as protect and release it on-demand. The 
binding ability of the polymers was determined by an agarose gel DNA retardation 
assay. Polymer and pDNA were mixed together to form polymer/pDNA complexes 
or polyplexes, and the binding ability measured by running the polyplexes on an 
agarose gel. Migration of pDNA is hindered when completely bound to the polymer, 
and in some cases pDNA can be seen within the wells of the agarose gel. By 
varying the N/P ratios (i.e. the molar ratio of nitrogen atoms on the polymer to 
phosphate atoms on the DNA backbone), we determined the minimal N/P ratio 
required for complete binding and polyplex formation. All polymers bound strongly 
to pDNA at N/P ratios as low as 2.5, determined from the little or no migration of 
pDNA through the gel, or the observed pDNA in the wells of the gel (Figure 2-1 and 
Appendix A Figure A2-1). 
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Figure 2-1: Agarose gel DNA retardation assay of P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-
C2 and A-C3)/pDNA complexes and PEI/pDNA complex. Complexes formed using 1 µg of 
pDNA at different N/P ratios (0.5-20). PEI/pDNA complexed at 4:1 (w/w). Complexes 
incubated at RT for 30 min (PEI 4 h) before running on a 1% agarose gel at 90 V for 30 
minutes.  
 
2.4.2 Polymer/DNA Sizing 
The size and overall charge of the polyplex (i.e. polymer complexed to pDNA) play 
an important role in cellular entry. The hydrodynamic diameter and zeta potential of 
the polyplexes were measured using dynamic light scattering (DLS). The N/P ratio 
that allowed good formation of polyplexes ranged from 5 to 50, as determined from 
the binding studies in Figure 1. The PEI polyplex (4:1 w/w to pDNA) gave a 
hydrodynamic diameter of 121.8 nm with a polydispersity index (PDIDLS) of 0.301, 
representing a broad size distribution. It should be noted that a PDIDLS value less 
than 0.1 represent narrow size distribution. All the polymers gave sizes ranging from 
100 to 200 nm with broad size distributions (Table 2-1). The only narrow size 
distributions were observed for the A-B series polyplexes (i.e. PDIDLS < 0.1) at the 
higher N/P ratios. The zeta potential for all the polyplexes ranged from +21 to +36, 
supporting the formation of positively charged polyplexes (see Appendix A Table 
A2-1). These values are comparable to the zeta potential of the PEI complex (+35.2 
mV). This, together with the similar size, suggests that our polymer polyplexes have 
very similar physical characteristics to the PEI polyplex.  
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Table 2-1: Size of P(DMAEA) (A), P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) complexes with pDNA (16 µg) in water at different N/P ratios (5, 25 
and 50). PEI/pDNA complex 4:1 (w/w) 121.8 nm (0.301). Dh data reported as an average 
of five Z-average measurements.  
 N/P 
Ratio 
Z- average hydrodynamic diameter, Dh (nm) (PDI in parentheses) 
A A-B1 A-B2 A-B3 A-C1 A-C2 A-C3 A-D1 A-D2 A-D3 
5 
156.2 
(0.119) 
108.9 
(0.215) 
93.9 
(0.257) 
99.2 
(0.271) 
113.7 
(0.108) 
130.0 
(0.104) 
157.3 
(0.133) 
112.3 
(0.393) 
185.2 
(0.295) 
170.9 
(0.405) 
25 
351.2 
(0.240) 
148.1 
(0.091) 
129.0 
(0.097) 
132.6 
(0.122) 
140.5 
(0.193) 
136.4 
(0.184) 
129.0 
(0.187) 
115.3 
(0.255) 
142.9 
(0.212) 
125.2 
(0.197) 
50 
1305.6 
(0.578) 
203.5 
(0.052) 
199.9 
(0.090) 
134.2 
(0.064) 
129.4 
(0.162) 
135.5 
(0.258) 
128.6 
(0.234) 
129.0 
(0.178) 
135.4 
(0.188) 
144.5 
(0.215) 
 
 
2.4.3 Polymer/DNA Release 
One of the objectives of this work was to determine if releasing pDNA in a time-
dependent manner could provide insight into the mechanism of transfection. Our 
previous work, using a polyplex of siRNA and A-C3, demonstrated that the siRNA 
could be fully released after 17 h, which is close to the time of 24 h for a mitotic 
event. By varying the release time using the range of designed polymers in this 
work, we wanted to investigate whether delivery into the nucleus occurred via 
passive transport (i.e. entry during mitosis) or via entry through the nuclear pores.  
 
The polyplexes were complexed in water and incubated at 37 °C for 4, 24, 48, 72 
and 168 h, where the unbound pDNA was monitored by an agarose gel (Figure 2-
2). Surprisingly, PEI showed no release of pDNA even after 168 h. Polymer A 
showed release of pDNA after 24 h and complete release at 168 h determined by 
the dark band corresponding to the free pDNA (see first lane in Figure 2-2). The 
dark smear on the gel prior to this time (between 24 to 72 h) represents partial 
release of the pDNA. The A-B series showed partial release after 48 h, and 
complete release at 72 h. The A-C series, with the exception of A-C1, partially 
released pDNA after 48 h with complete release well after 168 h. The same trend 
was observed for the A-D series. The subtleties in the release times suggest that all 
polymers strongly bind at 24 h, and only A-C2 and A-C3 show little release after 48 
 33 
 
h. These results demonstrate that the different polymers have different release rates 
due to the different copolymer compositions of the polymers and the size of the 
polyplex. For example, A-C3 formed small 20 nm particles in water that grew to 200 
nm when complexed with siRNA, whereas the A-B and A-D series polymers were 
fully water soluble (~9 nm) and formed polyplexes of ~200 nm.23a 
 
 
 
Figure 2-2: Time-release of pDNA from P(DMAEA) (A), P(DMAEA-b-ImPAA) (A-B1, A-B2 
and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3) and P(DMAEA-b-(DMA-
co-BA)) (A-D1, A-D2 and A-D3) at N/P10, and PEI at 4:1 (w/w). Samples run at time points 
indicated on a 1% agarose gel at 90 V for 30 min. 
 
2.4.4 Polymers/DNA Protection 
Protection of the pDNA before nucleus entry is of vital importance due to the many 
cellular enzymes that degrade and significantly lower the efficiency of the pDNA. 
The ability of the polymers to protect the pDNA from DNase I was determined using 
the following procedure: (i) the polyplex was exposed to DNase I for 2 h, (ii) after 
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this time the DNase I was inactivated, and (iii) the protected pDNA was released 
from the polymer using heparin, and the amount of pDNA measured on an agarose 
gel (see Figure 2-3). The levels of pDNA was measured after 30 and 120 min 
(denoted as + in Figure 2-3) and compared to that in the absence of DNase I 
(denoted as - in Figure 2-3). It can be seen that PEI provides excellent protection of 
pDNA; the two higher bands most probably represent conformational changes to 
pDNA.24 Most of the polymers provided some level of protection. The A-B series 
and A-D2 and A-D3 provided a low level of protection, whereas the A-C1 and A-C2 
gave no protection. Polymer A-C3 and A-D1 showed similar levels of protection 
compared to PEI. The results suggest that stronger binding of the pDNA to the 
cationic polymer provides a higher level of protection against nucleases found within 
the cell. 
 
 
 
Figure 2-3: DNase I protection assays. P(DMAEA) (A), P(DMAEA-b-ImPAA) (A-B1, A-B2 
and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-
co-BA)) (A-D1, A-D2 and A-D3) polymers complexed with pDNA at N/P 20, and PEI 
complex with pDNA at 4:1(w/w). Complexes exposed to DNase I for either 30 or 120 min 
before inactivation and release of pDNA by heparin. Released pDNA assessed on a 1% 
agarose gel at 90 V for 30 min.  
 
2.4.5 Polymer/DNA Endosome Escape and Gene Expression 
Our polymers have shown the ability to be able to bind, condense, protect and 
release pDNA. The next step is to determine if the polyplexes are able to cross the 
negatively charged cell membrane, escape the endosome, enter the nucleus, and 
produce protein (i.e. transfection). The addition of Cy5-labelled pDNA to the 
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polymers allowed us to visualize the uptake of the polyplexes into the cell. The 
confocal images showed the cell nucleus in blue, and pDNA in red (Figure 2-4). Our 
results showed that polymers A, A-B3, A-C3, and A-D3/pDNA polyplexes were able 
to cross the cell membrane, and become internalised, as pDNA can be seen within 
the cell as indicated by the red areas.  
 
 
 
Figure 2-4: Fixed-cell confocal microscopy 4 h post-transfection showing internalisation of 
Cy5-pDNA (red) complexes of P(DMAEA) (A), P(DMAEA-b-ImPAA) (A-B3), P(DMAEA-b-
(ImPAA-co-BA)) (A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-D3) in HEK293 cells. Cells 
were stained with DAPI to visualise the nucleus (blue). 
 
Internalisation via endocytosis (believed to be the main method for internalisation of 
polyplexes) is only half the story in terms of successful transfection. Once in the 
cell, the polyplexes must escape the endosome, transverse the cytosol, enter the 
nucleus, and release the pDNA. Based on our previous work, the A-C series 
showed excellent endosome escape when complexed to siRNA, while A, A-B and 
A-D series were less efficient.23a The combination of the ImPAA and BA monomers 
in the second block worked together to bind to the endosome membrane and allow 
escape. We decided to test all the polymers for their ability to escape the endosome 
and enter the nucleus in HEK293 cells. By adding chloroquine, a lysosomotropic 
agent that causes the endosomes to swell and burst, releasing all its contents into 
the cytosol, we could determine whether gene expression was directly related to the 
level of endosome escape. 
 
Transfection was performed in cells pre-treated with chloroquine for an hour and 
compared with untreated cells. The efficiency of endosomal escape and nuclear 
entry was measured using green fluorescence protein (GFP) expression by flow 
cytometry, with transfection efficiency measured as a percentage of cells 
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expressing GFP. The addition of chloroquine did not induce any toxic effects to the 
cells as cell viability remained similar between the non-treated and treated cells 
(Figure 2-5B, D and F). All polymers from the A-B, A-C, and A-D series were able to 
achieve transfection without the addition of chloroquine, while polymer A required 
the addition of chloroquine to achieve transfection (Figure 2-5A, C and E and 
Appendix A Figure A2-2). For the A-B series polymers, an increase in transfection 
efficiency can be seen in the cells treated with chloroquine compared with those not 
treated. Polymers A-C2 and A-C3 are highly efficient at endosomal escape, as the 
difference between efficiency between treated and non-treated cells is minimal. 
These polymers were able to achieve GFP expression in more than 95% of cells. At 
an N/P ratio of 5, the A-D series polymers in the presence of chloroquine displayed 
an increased in efficiency compare with cells in the absence of chloroquine, and no 
difference was observed at higher N/P ratios.  
 
Our results demonstrated that the addition of chloroquine increased transfection 
efficiency in the A-B series polymers at all N/P ratios tested and A-D series 
polymers as the lowest N/P ratio tested, suggesting that escape from the endosome 
was a limiting factor for these two polymer series. The second blocks of ImPAA or 
BA were unable to promote efficient endosome escape. For the A-C series 
polymers, escape from the endosome was efficient as no significant increase in 
transfection was observed in cells treated with chloroquine, suggesting that the 
combination of ImPAA and BA promotes efficient escape, similar to the results 
obtained by the siRNA knockdown study.23a By adding chloroquine, we reduced the 
possibility of endosome escape being the limiting factor in transfection; therefore, 
differences in transfection efficiencies between the polymer series must be due to 
either entry into the nucleus, or pDNA protection. We found that all polymers were 
able to bind the pDNA until 24 h, after which time release begins, and was of 
sufficient time to escape the endosome and travel to the nucleus for passive entry 
during mitosis. Our results show that the longer it took for the polymers to release 
the pDNA an increased in gene expression levels was observed, with polymer A-C3 
(N/P=5) found to be the best transfection agent. This strongly supports that by 
strongly binding with little or no release and protecting the pDNA, the polymer 
provided the best opportunity for entry into the nucleus during mitosis. The sizes of 
the polyplexes were significantly greater than the nuclear pores, which on a physical 
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basis discounts delivery directly through these pores. However, the mechanism is 
complex, and delivery through the pores cannot be discounted. 
 
 
A-B1 A-B2 A-B3 A-B1 A-B2 A-B3
A-C1 A-C2 A-C3 A-C1 A-C2 A-C3
A-D1 A-D2 A-D3 A-D1 A-D2 A-D3
 
 
Figure 2-5: Endosomal escape assays for P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) at various N/P ratios in HEK293 cells pre-treated with and without 100 
µM chloroquine. Results measured 48 h post-transfection. (A), (C) and (E) transfection 
efficiency (B), (D) and (F) cell viability. Data reported as the mean ± standard error of the 
mean of two replicates.  N/P ratios are in parenthesis. 
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2.4.6 Efficient Gene Expression Requires Optimal Ratios of Plasmid to Polymer 
Optimum N/P ratios for each of the polymers were determined for efficient 
transfection with minimal cellular toxicity. A range of N/P ratios (5-30) were tested 
for each polymer and transfection efficiency measured 48 h later by flow cytometry 
(Figure 2-6). Cellular toxicity of the polymers was considered to be an issue when 
the cell viability dropped below 90%. Each of the polymers within the A-B series at 
an N/P ratio of 20 and 30 displayed similar results with A-B3 able to achieve around 
50% transfection efficiency (Figure 2-6 and Appendix A Figure A2-3). This indicated 
that the optimum N/P ratio lies within this range with little cell death observed at 
these N/P ratios. For A-C series, little difference in transfection efficiency was 
observed at N/P ratios 5 and 10 but at the higher ratio, cell death became a 
significant issue with cell viability dropping below 80% for A-C3 (Figure 2-6 and 
Appendix A Figure A2-4). For the A-D series polymers higher levels of transfection 
efficiency could be achieved at N/P ratio of 10 and above, but once again at this 
ratio toxicity became a major issue, resulting in an optimum N/P ratio of 5 (Figure 2-
6 and Appendix A Figure A2-5). 
 
 
 
A-B3 A-C3 A-D3 A-B3 A-C3 A-D3
 
Figure 2-6: Transfection efficiency and cellular viability of P(DMAEA-b-ImPAA) A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-D3) at various 
N/P ratios in HEK293 cells 48 h post-transfection. (A) Cell density and viability and (B) 
transfection efficiency. Data reported as the mean ± standard error of the mean of two 
replicates. N/P ratios are in parenthesis. 
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2.5 Conclusions 
This work described the abilities of novel polymers as transfection reagents for 
transient gene expression. The polymers all contain the same first block, PDMAEA, 
which was able to bind and then release pDNA in a time-dependent manner. Our 
results showed that release of pDNA occurred after 24 h, which was sufficient time 
for the polymer/pDNA complexes to escape the endosome and travel to the nucleus 
and enter when the nuclear membrane is disintegrated during cell division. This is 
believed to be the main method of entry as the size of the polyplexes (100-200 nm) 
makes them virtually impossible to passively enter the nucleus through the nuclear 
pores (~25 nm), although other modes of active nucleus entry cannot ruled out. Our 
best polymer A-C3, which has the combination of ImPAA and BA blocks, was 
efficient at endosome escape determined from the high transfection efficiency even 
with the addition of chloroquine. A-C3 also provided the best protection against 
DNase I compared to the other polymers, as well as it bound the pDNA the longest 
period of time. We were able to achieve transfection efficiency of 95% with A-C3, 
which was much greater than the commercially available Freestyle Max. The 
polymer A-C3 provides sufficient protection of the pDNA until nucleus internalisation 
occurs. Current transfection agents rely on a stochastic and unpredictable program 
of DNA release after cellular entry, the polymers developed in this work offer a 
tuneable and controlled process of DNA release.  These properties make these 
reagents an attractive option for the timed release of DNA. For example, these 
timed-release polymers could be used to deliver DNA in slow growing cells or cells 
that are difficult to transfect using traditional methods (e.g. neurons). Moreover 
these polymers have a defined structure that can be readily be modified depending 
on circumstances (i.e. addition of ligands for use in targeting specific cell types), 
and are inexpensive to produce compared to the commercially available lipid-based 
transfection reagents, Lipofectamine and Freestyle Max. 
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Chapter 3 – Intracellular Trafficking Pathways for Nuclear Delivery of Plasmid 
DNA Complexed with Highly Efficient Endosome Escape Polymers  
 
3.1 Abstract 
Understanding the pathways for nuclear entry could see vast improvements in polymer 
design for the delivery of genetic materials to cells. Here, we use a novel diblock 
copolymer complexed with plasmid DNA (pDNA) to determine both its cellular entry and 
nuclear pathways. The diblock copolymer (A-C3) is specifically designed to bind and 
protect pDNA, release it at a specific time, but more importantly, rapidly escape the 
endosome. The copolymer was taken up by HEK293 cells preferentially via the clathrin-
mediated endocytosis (CME) pathway, and the pDNA entered the nucleus to produce 
high gene expression levels in all cells after 48 h, a similar observation to the 
commercially available polymer transfection agent, PEI Max. This demonstrates that the 
polymers must first escape the endosome and then mediate transport of pDNA to the 
nucleus for occurrence of gene expression. The amount of pDNA within the nucleus 
was found to be higher for our A-C3 polymer than PEI Max, with our polymer delivering 
7 times more pDNA than PEI Max after 24 h. We further found that entry into the 
nucleus was primarily through the small nuclear pores, and did not occur during mitosis 
when the nuclear envelope becomes compromised. The observation that the polymers 
are also found in the nuclear pore supports the hypothesis that the large pDNA/polymer 
complex (size ~ 200 nm) must dissociate prior to nuclear pore entry, and that cationic 
and hydrophobic monomer units on the polymer may facilitate active transport of the 
pDNA.  
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3.2 Introduction 
The delivery of plasmid DNA (pDNA) into mammalian cells is central to genetic 
engineering applications, including cell based biomedical research, gene therapy and the 
production of therapeutic recombinant proteins.1 Viral derived delivery vectors are still 
unparalleled in their ability to efficiently delivery their payload into the appropriate cellular 
environment (e.g. nucleus). However, issues with viral delivery systems include limited 
amounts of encapsulated DNA, immunogenicity, and many other safety concerns.2 
Polymers (i.e. non-viral vectors), on the other hand, are relatively easy to synthesize, have 
low toxicity, and able to be designed with unique chemical composition and topology.3 
Although considerable research has been carried out for the use of polymers as delivery 
devices for pDNA,4 there is a lack of understanding of how polymers enter the cells and 
deliver the pDNA into the nucleus. Due to the much larger size of the polymer/pDNA 
complexes (~50-200 nm) compared to the size of nuclear pores (~25 nm), it is believed 
that delivery of the complex is during cell division when the nuclear envelop is temporarily 
disintegrated.5 The observation of PEI (the most used polymer for pDNA delivery) within 
the nucleus of non-dividing cells counters the above argument, and suggests active or 
passive transport of the complex through the nuclear pore complexes (NPC).6  
 
The ability to manipulate, through its polymer composition, the polymer's physical behavior 
under different environments will lead to the next generation of artificial (non-viral) vectors 
that mimic similar cunning mechanisms that viruses have developed. The influenza A 
virus, for example, enters cells through endocytosis, and escapes this low pH environment 
via a transformation of its structure that binds with the endosomal membrane.7 Once in the 
cytosol (pH ~7.4), it reconstitutes back into its original structure. Our group developed a 
novel polymer complex that mimics this efficient escape mechanism from the endosome to 
the cytosol with excellent knockdown of protein production using siRNA (i.e. small 
interfering RNA).8 The polymer chain could bind to the negatively charged siRNA through 
positive electrostatic binding, change conformation in a low pH environment (e.g. pH ~ 
5.5), bind to the endosomal membrane and escape to the cytosol. This polymer 
component degrades from a cationic polymer poly(2-di methylaminoethyl acrylate), 
(PDMAEA) to an anionic polymer (poly(acrylic acid)), a hydrolysis mechanism independent 
of the pH or molecular weight of the polymer.9 Incorporation of this polymer component 
into a diblock copolymer consisting of a second block of P(N-(3-(1H-imidazol-1-yl)propyl) 
acrylamide (PImPAA) and poly(butyl acrylate) (PBA) (see Scheme 3-1A) via the single 
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electron transfer - 'living' radical polymerization (SET-LRP)10 technique produced a 
polymer system that could be taken up by cells in less than 4 h, escape the endosome 
mimicking the influenza virus mechanism, and release all siRNA into the cytosol to down 
regulate specific proteins.8  
 
The aim of this work is to determine the pathways of cell uptake and nuclear entry of our 
diblock copolymer P(DMAEA-b-(ImPAA-co-BA)) with pDNA to HEK293 cells, and compare 
this polymer to two commercially available transfection agents, PEI Max and Freestyle 
Max (a liposome-based delivery device). It is generally accepted that cellular 
internalization of polymer/DNA complexes (polyplexes) and liposome/DNA complexes 
(lipoplexes) is via endocytosis.11 There are several different endosomal pathways that are 
usually divided into four groups: phagocytosis, clathrin-mediated endocytosis, caveolae-
mediated endocytosis and macropinocytosis.12 The last three can also be classified as 
pinocytosis. We will employ various chemical inhibitors (see Scheme 3-1B) to determine 
the endocytosis pathway taken for entry of the various non-viral polyplexes/lipoplexes 
vectors. Previous results show that the endocytosis pathway is dependent on both cell-line 
and vector type.13 Entry of the non-viral vectors into the nucleus is paramount for 
transfection (i.e. protein production). The addition of the nuclear pore inhibitor, wheat germ 
agglutinin (WGA)14, will allow us to ascertain whether nuclear pore entry is the dominant 
pathway over entry via disintegration of the nuclear envelope during cell division. The 
pDNA we use in this study is greater than 3 MDa, which is thought to be too large to enter 
the NPC without active transport.15 HEK293 cells are a robust and are easily transfected, 
making them ideal hosts for the production of recombinant proteins in the pharmaceutical 
industry. The HEK293 cells used in this study are an asynchronous population, but all 
transfection studies are performed on cells maintained in the exponential growth phase of 
the growth cycle.  
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Scheme 3-1: (A) Chemical structure and number of repeating units of P(DMAEA-b-
(ImPAA-co-BA)) (A-C1, A-C2 and A-C3). (B) Pathways involved in the cellular and 
nuclear uptake of polyplexes and lipoplexes, and inhibitors used to stop these 
pathways. 
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3.3 Materials and Methods 
3.3.1 Synthesis of P(DMAEA-b-(ImPAA-co-BA)) by SET-LRP (A-CX) 
Oregon green 488 labeled A-C3 was synthesized according following procedures (see 
Appendix B Scheme B3-1): Synthesis of polymer A-C series can be found in the 
reference.8a A typical polymerization was as follows: P(DMAEA65)-Cl (0.840g, 8.4 x 10-5 
mol), ImPAA (1.500g, 8.4 x 10-3 mol), BA (0.540g, 4.2 x 10-3 mol) and Me6TREN (0.039g, 
1.7 x 10-4 mol) were dissolved in methanol (2 mL) and the solution was purged with argon 
for 30 min. CuCl (0.017g, 1.7 x 10-4 mol) was added under argon flow. The reaction was 
stirred at room temperature for 15 h, diluted with acetone (10 mL) and passed through 
Al2O3 (basic) to remove copper. The products were dialysed against methanol (3x250 mL) 
to remove monomer. The solvent was removed by rotavap and the product was recovered 
by precipitating in acetone/n-hexane mixture (10 mL, 4/6, v/v) and isolated by centrifuging. 
This procedure was repeated three times. The product was dried under high vacuum for 
48 h to give a yellow sticky solid (yield 34%). The conversion of polymerization as 
determined by 1H NMR spectroscopy was 31% and 40% for ImPAA and BA, respectively. 
Mn = 24000, PDI = 1.25 (SEC-RI calibrated using PSTY Standards and used DMAc + 0.03 
wt% LiCl as eluent). 
 
3.3.2 Synthesis and Modification of Polymers with Fluorescent Tag 
Synthesis of novel polymer A-C series can be found in the reference.8a PEI Max was 
labeled with FITC-isothiocyanate according previous report.16  
(i) Synthesis of 2-(2-pyridyl disulfide)ethyl 2-chloropropanoate: to a cold solution (ice-
bath) of 2-hydroxyethyl pyridyldisulfide17 (0.50 g, 2.67 x 10-3 mol) and TEA (0.44 mL, 3.21 
x 10-3 mol) in 20 mL of dry DCM,  2-chloropropionyl chloride (0.28 mL, 2.94 x 10-3 mol) in 
10 ml of dry DCM was added drop-wise in 30 min. The mixture was stirred overnight 
(~15h). Solvent was removed by rotary evaporation. 100 mL diethyl ether was added to 
dissolve the product and the salt was filtered out. The product was purified by flash column 
chromatography using silica gel as stationary phase and mixture of ethyl 
acetate/petroleum spirit (1/3, v/v) as eluent (Rf=0.42), yield=71%. 
1H NMR (CDCl3, 500 MHz) (ppm): 8.45 (m, 1H, aromatic proton, ortho-N), 7.64 (m, 1H, 
aromatic proton, meta-N and para-N), 7.08 (m, 1H, aromatic proton, ortho-disulfide 
linkage), 4.41 (2H, t, J=6.4 Hz, -(C=O)-OCH2-), 4.36 (1H, q, J=6.9 Hz, -(CH3)CHCl), 3.05 
(2H, t, J=6.4 Hz, -S-SCH2-), 1.66 (1H, d, J=6.9 Hz, -(CH3)CHCl); 13C NMR (CDCl3, 
500MHz) (ppm) 169.3, 159.5, 149.3, 137.2, 121.1, 120.0, 63.6, 52.4, 37.1, 21.9. 
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(ii) Synthesis of pyridyldisulfide functional A-C3 copolymer (PDS-A-C3): By using 2-(2-
pyridyl disulfide)ethyl 2-chloropropanoate as initiator, the pyridyl disulphide functional 
copolymer synthesis, purification and characterization were the same as the synthesis of 
A-C3 in the reference.8a The final composition of PDS-A-C3 was confirmed by 1H NMR as 
PDS-P(DMAEA65-b-(ImPAA41-co-BA30) and triple detection (TD) SEC.: Mn(TD)=25000, 
PDI=1.25, Mn(NMR)=20200. 
(iii) Synthesis of Oregon green 488 labeled A-C3: PDS-A-C3 (50 mg, 2.0 x 10-6 mol) 
and Oregon green 488 maleimide (1.0 mg, 2.0 x 10-6 mol) were dissolved in methanol (0.5 
mL). TCEP (5 mg, 2.0 x 10-5 mol) was dissolved in methanol (0.3 mL). Two solutions were 
purged Argon separately for 5 min. TCEP solution was added into polymer and dye 
solution. The reaction was sealed and stirred for 15 h at room temperature under argon 
atmosphere. The conjugation efficiency was determined by DMAc SEC with UV-Vis 
detector at 518 nm. The conjugation efficiency was 25% (see Appendix B Figure B3-1). 
The solution was then centrifuged using centrifuge filtered (10000 MWCO, Merk-Milipore) 
to concentrated polymer and removed TCEP and pyridine-2-thiol. The centrifugation was 
repeated 6 times by adding 600 µL of fresh methanol each time. The final product was 
recovered by evaporation of methanol under high vacuum. 
 
3.3.3 Transfection Studies 
HEK293 cells were passage routinely in Freestyle 293 (Life Technologies). Cell density on 
the day of transfection was 2x106 cells/mL. Transfections were performed in 2 mL in 6-well 
non-tissue culture plates. Polyplexes were prepared in sterile water (25% of the initial 
culture volume) at N/P ratios 5/1 (optimum ratio previously establish in Chapter 2 or 
reference18) using 2 µg DNA (pEGFP or pmCherry) per mL of culture. Polyplexes were 
vortex for 30 s and left at RT for 30 min before addition to the cells. PEI Max 
(Polysciences) was prepared at 4/1 (w/w, polymer/pDNA). Each component was diluted 
separately using OptiPro SFM (Life Technologies) and incubated at room temperature for 
a minute, mixed and left for a further 20 min before addition to cells. Freestyle Max (Life 
Technologies) was prepared according to the manufacturer’s protocols with cell culture 
volume at 2 mL. Transfected cultures were incubated at 37 °C in a humidified 7.5% CO2 
atmosphere on an orbital shaker at 130 rpm until 4 h post-transfection where cultures were 
fed with an equal volume of Freestyle 293 supplemented with 0.4% ACA (v/v) (Life 
Technologies). The cultures were then placed back into the incubator. Transfection 
efficiency was measured 48 h post-transfection via the FACSAria II (BD, San Jose, CA). 
Transfection efficiency is defined is the number of fluorescing cells in the transfected 
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population. Ten thousand events were measured per sample. Cell density and viability 
were measured using an automated trypan blue exclusion assaying using the Cedex 
HiRes Cell Counter (Innovatis AG, Bielefield, Germany) or Countess® Automated Cell 
Counter (Life Technologies). 
 
3.3.4 Chemical Inhibitors – Cellular Uptake 
To investigate cellular uptake of polyplexes, cells were pre-incubated with the following 
chemicals for 30-60 min before transfection: chlorpromazine (final concentration 10 
µg/mL), filipin III (final concentration 1 µg/mL), dynasore (final concentration 25 µg/mL) or 
amiloride (final concentration 30 ng/mL). Cells were transfected as in Section 3.3.2 with 
transfection efficiency, cell density and cell viability measured 48 h post-transfection. 
 
3.3.5 Chemical Inhibitors – Nuclear Entry 
To investigate nuclear entry of pDNA, cells were pre-incubated for 30 min before 
transfection with wheat germ agglutinin (final concentration 50 µg/mL). Cells were 
transfected as in Section 3.3.2 with transfection efficiency, cell density and cell viability 
measured 48 h post-transfection. 
 
3.3.6 FACs – Polyplex Uptake and Nuclei Isolation 
Transfections were performed as in Sections 3.3.2 and 3.3.4 expect that labeled PEI Max 
and labeled A-C3 were used instead (see Section 3.3.2). At the required time points whole 
cells were measured by flow cytometry for both transfection efficiency (measurement of 
the percentage of cells expressing protein of interest) and uptake of labeled polymers. For 
nuclei isolation 2.5-3x106 cells/mL were collected, stained with Hoechst 33342 (Life 
Technologies) and pelleted using a benchtop centrifuge at 3000 rpm for 10 min at the 
required time points. Cell pellet was washed twice with ice cold PBS buffer before lysising 
with lysis buffer (1 M Hepes, 3 M KCl, 0.25 M EDTA and 10% NP40). Extracted nuclei 
were pelleted using a benchtop centrifuge at 3000 rpm for 10 min before resuspending in 
PBS. The extracted nuclei were run on the FACSAria II (BD Bioscience, San Jose, CA) 
and sorted based on signal from the Hoeschst stain. For each sample 125, 000 events 
were collected using the flow cytometer for real-time PCR.  
 
3.3.7 Real-Time PCR 
Isolation of total DNA was performed on both the sorted extracted nuclei and whole cells 
using the ISOLATE II Genomic DNA Kit (Bioline). For relative quantitation of pDNA 
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isolation of genomic and pDNA from sorted extracted nuclei was used neat and for whole 
samples a 1/10 dilution was used.   Final volume of the PCR mixture was 10 µL and 
consisted of SYBR® Select Master Mix (Applied Biosystems®), 2 µL of sample, sterile 
water and specific primers for pEGFP (forward; 5’-CTGCTGCCCGACAACCA-3’ and 
reverse 5’- TGTGATCGCGCTTCTCGTT-3’;) or pmCherry (forward;5’-
CCTGTCCCCTCAGTTCATGT-3’ and reverse; 5’-CCCATGGTCTTCTTCTGCAT-3’) and 
for housekeeping gene GAPDH (forward; 5’-AAGGTCATCCCTGAGCTGAA-3’ and 
reverse; 5’-ACCTGGTGCTCAGTGTAGCC-3’). The reaction was performed on the ViiA™ 
7 (Applied Biosystems®) and the PCR cycle conditions were initial denaturation for 10 min 
at 95°C, followed by 40 cycles of 95 °C for 15 s, 60 °C for 1 min and 95 °C for 15 s. Data 
for the PCR was analysed using the ViiA™ 7 software (Applied Biosystems®) with relative 
quantification of pEGFP or pmCherry normalised to housekeeping gene GAPDH. For 
WGA inhibitory experiments transfections were performed with unlabeled polymers and 
pEGFP as the WGA was labelled with Alexa Fluor 647 which could interfere with mCherry 
signal on the FACS if pmCherry was used instead. 
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3.4 Results and Discussion 
3.4.1 Endocytosis Pathways 
The mechanism for cellular entry can be determined by using a range of chemical 
inhibitors to block the involvement of clathrin-mediated endocytosis (CME), caveolae-
mediated endocytosis (CvME) or macropinocytosis (see Scheme 3-1B). The preferred cell 
entry pathway in the HEK293 cells can be monitored through the production (i.e. 
transfection) of the eGFP marker. All entry studies used an N/P ratio of 5:1 (i.e. the molar 
ratio of nitrogen atoms on the polymer to phosphate atoms on the DNA backbone). This 
ratio was previously established to achieve the greatest level of transfection with minimal 
toxicity (Chapter 2 or reference18). Flow cytometry was used to quantify transfection 
efficiency with different chemical inhibitors calculated from the percentage of cells with a 
fluorescence signal from GFP expression and compared against controls of untreated 
cells. Three diblock copolymers (A-C series) were synthesized with the ImPAA and BA 
units increasing from 20 to 45 and 12 to 29, respectively. The transfection efficiencies after 
48 h for the three polymers complex with pEGFP increased from 85 to close to 100% with 
an increase in the number of ImPAA and BA units with minimal toxicity (Figure 3-1A, 
untreated). Freestyle Max, a commercially available liposome, gave approximately 63% 
transfection, suggesting our polymer's superior delivery over liposomes for HEK293 cells. 
The high level of transfection of the A-C polymers demonstrated the efficient escape from 
the endosome (similar to the data obtained for siRNA delivery8) and transport of the 
pEGFP into the nucleus.  
 
The addition of 10 µg/mL chlorpromazine will inhibit the CME pathway by interacting with 
clathrin from the coated pits, thereby reducing the amount of coated pits on the cell 
surface.19 The CME pathway is characterized by the formation of clathrin-coated pits with 
the average size of the resulting endocytic vesicle between 100-150 nm, which is then 
pinched off from the plasma membrane using the GTPase dynamin.11a, 20 The significant 
decrease in the level of transfection in the presence of CMZ for the three polymers and 
Freestyle Max (Figure 3-1A) suggests that this is one of the major endocytosis pathways. 
The addition of 1 µg/mL of filipin III inhibits the CvME pathway by specifically binding 
cholesterol on the cell surface to form filipin-sterol complexes rather than the coated pits, 
making it a selective inhibitor for the CvME pathway.21 The CvME pathway is 
characterized by flask-shaped membrane invaginations that are lined with caveolin and 
enriched with cholesterol and sphongolipids.20b The size of the resulting endocytic vesicle 
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is typically between 50-80 nm.22 Pathogens taken up by this endocytic pathway are usually 
directly transported to Golgi and/or endoplasmic reticulum avoiding any lysosomal 
degradation.12 The mechanism behind such an evasive process still remains to be 
elucidated.23 Transfection decreases for Freestyle Max and A-C1, whereas the A-C2 and 
A-C3 polymers are only slightly affected (Figure 3-1B). Inhibition with 25 µg/mL of 
Dynasore, a dual acting inhibitor for both CME and CvME,24 results in a significant 
decrease in all transfection efficiencies for Freestyle Max and the three polymers (Figure 
3-1C). These results suggest that Freestyle Max and A-C1 can enter the cell via both the 
CvME and CME pathways, whilst A-C2 and A-C3 prefer the CME pathway. 
Macropinocytosis differs from the previous two endocytosis pathways through the 
formation of actin-driven membrane protrusions that collapse and fuse with the plasma 
membrane producing large endocytic vesicles (> 1 µm in diameter).25 Amiloride inhibits the 
macropinocytosis pathway by inhibiting the Na+/H+ exchange required for ruffling.26 The 
addition of 30 ng/mL amiloride to HEK293 cells before transfection shows no significant 
change in the transfection efficiency of Freestyle Max in cells treated with and without this 
inhibitor (Figure 3-1D). The polymers A-C1, A-C2 and A-C3 shows a decrease in 
transfection efficiency by 49, 34 and 17%, respectively. The data suggests that the greater 
number of units of ImPAA and BA in the second block (A-C3) has a distinct preference for 
the CME pathway. Decreasing the units of ImPAA and BA results in greater entry through 
the other three pathways, in which for example A-C1 preferentially enters via CME and 
CvME and a small fraction through macropinocytosis. 
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Figure 3-1: Effect of endocytosis inhibitors on transfection efficiency. HEK293 cells were 
pre-treated with inhibitors prior to transfection. Flow cytometry analysis was performed on 
the cells 48 h post-transfection to assess the level of GFP fluorescence. Percentage of 
cells expressing GFP measured by flow cytometry (A) Chlorpromazine (10 µg/mL), (B) 
Filipin III (1 µg/mL), (C) Dynasore (25 µg/mL) and (D) Amiloride (30 ng/mL). Data reported 
as the mean ± standard error of the mean of two replicates. N/P ratios are in parenthesis. 
 
3.4.2 Kinetics of Gene Expression 
We next compared the rate of transfection efficiency from 30 min to 48 h for A-C3, PEI 
Max and Freestyle Max (Figure 3-2). The A-C3 polymer was chosen as it showed the 
greatest transfection efficiency compared to A-C1 or A-C2. It is found that after 0.5 h, the 
transfection efficiency was below 1% for all systems tested. After 8 h, PEI Max shows the 
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highest transfection (close to 30%), followed by Freestyle Max (21%), with only a very 
small amount for A-C3 (7%). At 24 h, A-C3 gave the greatest transfection (68%) with 
similar value for PEI Max (63%) and Freestyle Max lower (50%). The A-C3 and PEI Max 
reach 92% transfection after 48 h, whilst Freestyle Max is only 57%. The results suggest 
that although A-C3 has a slow initial rate of transfection, its transfection is equal to or 
better than PEI Max for HEK293 cells at 24 h. 
 
It was previously found that even though the A-C polymer series can fully release siRNA 
after 17 to 20 h,8a, 27 the time for complete release of pDNA when complexed to A-C1, A-
C2 and A-C3 was after 24, 72 and 72 h, respectively.18 This showed that the complexation 
of siRNA to the A-C polymer series was different to the complexation of the same 
polymers to pDNA. Protection of the pDNA when complexed to A-C3 in the presence of 
DNase I was also much better compared to A-C1 or A-C2. This together with the greatest 
transfection for A-C3 (Figure 3-1, untreated cells) suggested that prolonged binding 
advantageously increases transfection, and the partial release of pDNA after 24 h could 
result in even greater transfection efficiencies over time.  
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Figure 3-2: Kinetics involved in gene expression over 48 h post-transfection. PEI Max 
polyplexes were formed at polymer/DNA ratio of 4/1 (w/w), Freestyle Max lipoplexes 
formed at lipid/DNA ratio of 1/1 (v/w), and A-C3 polyplexes formed at N/P ratio of 5/1. Data 
reported as the mean ± standard error of the mean of three replicates. 
 
3.4.3 Uptake Kinetics of Labelled Polymer within the Cell and Nucleus 
The data above demonstrated that the plasmid DNA (pEGFP) not only enters the nucleus 
but can be transcribed to produce GFP. The question we wanted to answer next was 
whether the A-C3 polymer also entered the nucleus, similar to that found for PEI in non-
dividing cells. PEI Max labelled with FITC and A-C3 labelled with Oregon Green were 
individually complexed with pmCherry. It was found that after 48 h nearly every cell 
(~100%) contained both PEI Max and A-C3 labeled polymers, and ~100% of all the cell's 
nuclei contained both the PEI Max and A-C3 polymers (see Appendix B Figure B3-3). The 
fluorescence level of the labelled polymer within the whole cell (including the nucleus) and 
the level of polymer that resided only within the nucleus was given in Figure 3-3. The level 
in the nucleus was significantly lower than the total fluorescence level, suggesting that only 
a small fraction of either PEI Max or A-C3 transported into the nucleus. Since the 
fluorescence levels for both polymers within the nucleus were relatively constant over the 
48 h period, we postulated that the polymers must enter through the NPC. The data does 
not distinguish between nuclear pore entry of polymer/plasmid complex or just of the 
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polymer. Based on the size of the uncomplexed A-C3 (~20 nm), the polymer would require 
active transport to pass through the NPC. We further suggest that the large size of the A-
C3/plasmid complex (~160 nm) will not transport either through active or passive diffusion, 
suggesting dissociation between the polymer and plasmid prior to or during pore entry. 
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Figure 3-3: Cellular uptake of labelled PEI-FITC and A-C3-Oregon green / pmCherry 
polyplexes in HEK293 cells. Both whole cells and extracted nuclei were analysed for 
labelled PEI Max and A-C3 polymer by flow cytometry. (A) PEI Max. PEI polyplexes were 
formed at polymer/DNA ratio of 4/1 (w/w). (B) A-C3. A-C3 polyplexes formed at N/P ratio 
of 5/1. Data reported as the mean ± standard error of the mean of three replicates. 
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3.4.4 Quantification of Delivery of pDNA to the Nucleus  
Transfection of pmCherry using either PEI Max or A-C3 to HEK293 cells resulted in little or 
no expression after 30 min (Figure 3-4A). Transfection for PEI Max increased steadily over 
time, reaching 100% after 48 h. On the other hand, A-C3 showed ~13% transfection after 
8 h, exhibiting the same transfection to that of PEI Max after 24 and 48 h. The amount of 
pDNA within the nucleus was quantified relative to the housekeeping gene, GAPDH. This 
ratio is defined as the copy number, and used in our study represents a relative change in 
pDNA to GAPDH. It was found in Figure 3-4B that pDNA (i.e. pmCherry) had a single-fold 
change in relative copy number of 1 after only 30 min for the A-C3 polymer system and 
over half-fold change in relative copy number for the PEI polymer system, confirming that 
transport of the pDNA into the nucleus was rapid. It also suggested that protein production 
had a lengthy lag time for both polymers until 24 h. In the case of PEI Max, the relative 
copy number increased from under a single-fold change (after 30 min) to 3-fold change by 
8 h followed by a decrease to below a single-fold change after 48 h. This supports a 
steady increase of pDNA up to 8 h into the NPC, followed by dilution of the pDNA through 
cell division (i.e. mitosis) after this period. On the other hand, the pDNA when transported 
with A-C3 showed a linear increase in copy number from 1 (after 0.5 h) to 5.2 (after 24 h) 
followed by a decrease to 2.2 after 48 h. The profiles of PEI Max and A-C3 were quite 
different, suggesting quite different entry mechanisms. One could infer from these profiles 
that PEI-Max mediated entry of pDNA was primarily though the nuclear pore in agreement 
with previous work, and A-C3 mediated entry most probably occurred through mitosis. 
However, different diffusion mechanisms of the polymer/pDNA complexes through the 
cytosol to the nucleus cannot be ruled out. 
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Figure 3-4: Quantification of pDNA copy number using qPCR. HEK293 cells were 
transfected with PEI Max or A-C3 / pmCherry polyplexes. The pDNA was extracted from 
the nuclei of HEK293 cells and quantified using qPCR. Copy number of pDNA was 
normalised to the housekeeping gene, GAPDH. (A) Expression of mCherry production and 
(B) relative copy number of pDNA in the nucleus of HEK293 cells transfected with either 
PEI Max or A-C3 polyplexes over a 48 hour period. PEI Max polyplexes were formed at 
polymer/DNA ratio of 4/1 (w/w), and A-C3 polyplexes formed at N/P ratio of 5/1. Data 
reported as the mean ± standard error of the mean of three replicates. 
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3.4.5 Pathway for Nuclear Pore Entry 
The true nature of transport through the nuclear pore is still unclear at this stage. The 
two main recognized entry mechanisms are through direct diffusion through the nuclear 
pore or for larger molecules (e.g. polymer/pDNA complexes) entry via mitosis when the 
nuclear envelope becomes compromised.28 As described above and also suggested from 
our previous work,18 the A-C3 polymer most probably mediated transport of the pDNA 
during mitosis. To test where the entry mechanism is through the NPC or via mitosis, we 
added an inhibitor, wheat germ agglutinin (WGA), known to block nuclear pores. It 
accomplishes this by binding to the N-acetyl glucosamine (GlcNAc) residues of the FG 
repeats of the nups.29 Mohr et al demonstrated that WGA crosslinks GlcNAc-containing 
FG repeating units, producing an additional mesh-like barrier that reduces the size of 
cargo that can enter the NPC, even naked pDNA.14a, 15b, 29b   
 
HEK293 cells were incubated with 50 µg/mL of WGA for 30 min before the addition of PEI 
Max or A-C3 polyplexes. The addition of WGA significantly reduced the transfection 
efficiency after 48 h to < 10% for both PEI Max and A-C3 (Figure 3-5), and we confirmed 
that this was not a result of any toxicity of the WGA (see Appendix B Figure B3-5). We 
further found that WGA had a small inhibitory effect on entry to the cell (Figure 3-6). The 
results clearly demonstrate that both PEI Max and A-C3 mediated delivery of pDNA is 
primarily through the nuclear pores. Mitosis, surprisingly, can be ruled out as the cells 
undergo at least one cell division over 48 h, and would provide the opportunity for entry via 
mitosis after 24 h. If this were the case, a much higher copy number would have been 
logically observed in the nuclei in the presence of WGA at 50 µg/mL for both polymer 
systems, which was not the case as shown in Figure 3-6. It has been documented that 
entry through the NPC is facilitated by hydrophobic interactions between the cargo and the 
FG filaments of the nuclear pore.30 The second block of the A-C3 polymer contains butyl 
acrylate units that not only enhance endosomal escape but perhaps binds to the nuclear 
pore facilitating pDNA transport through the NPC; a postulate supported through the 
greater transfection efficiency of A-C3 compared to diblocks without the butyl acrylate 
units18. This together with the A-C3's capability to protect the pDNA may explain the 
polymer's high transfection efficiency to HEK293 cells. 
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Figure 3-5: Analysis of nuclear entry through wheat germ agglutinin (WGA) treatment. 
Transfection efficiency of PEI Max and A-C3 / pEGFP polyplexes in HEK293 cells treated 
with 50 µg/mL WGA 48 h post-transfection. Transfection efficiency measured on the 
percentage of cells expressing GFP as measured by flow cytometry. PEI Max polyplexes 
were formed at polymer/DNA ratio of 4/1 (w/w), and A-C3 polyplexes formed at N/P ratio of 
5/1. Data reported as the mean ± standard error of the mean of four replicates. 
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Figure 3-6: Relative copy number of pDNA in HEK293 cells treated with 50 µg/mL wheat 
germ agglutinin (WGA) and transfected with either PEI Max or A-C3, 48 h post-
transfection. Cells were transfected with pEGFP and copy number of pDNA was measured 
by qPCR and normalised to the housekeeping gene, GAPDH. PEI Max polyplexes were 
formed at polymer/DNA ratio of 4/1 (w/w), and A-C3 polyplexes formed at N/P ratio of 5/1. 
Data reported as the mean ± standard error of the mean of three replicates. 
 
3.5 Conclusion 
In summary, this work demonstrated the entry pathways of plasmid DNA/polymer 
complexes into the cell and then into the nucleus. The A-C3 polymer/pDNA complexes 
preferred the clathrin-mediated endocytosis (CME) cellular entry pathway. The polymers 
used in this study consisted of functionality that allowed for rapid escape from the 
endosome. It was found that the commercial transfection agents, PEI Max and Freestyle 
Max, initially had a much greater gene expression than our A-C3 polymer. At 48 h post-
transfection, expression from the A-C3 complex was similar to PEI Max and much higher 
than Freestyle Max. We also found that within the nucleus of cells the pDNA copy number 
transfected with PEI Max was less at all-time points tested compared to cells transfected 
with A-C3. Transfection was inhibited when we added the pore-blocking compound, WGA, 
supporting that entry into the nucleus was through the nuclear pores and not when the 
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nuclear envelope becomes compromised during cell division. It was confirmed that both 
PEI Max and A-C3 fluorescence labeled polymers also entered the nucleus, presumably 
through the hydrophobic interactions of the polymer (i.e. the butyl acrylate units on A-C3) 
with hydrophobic moieties within the pore. Taken together, the data suggested that there 
should be dissociation of the large pDNA/polymer complex prior to nuclear entry, most 
likely on the nuclear membrane or in the nuclear pore. This data also suggested that 
transport of the large pDNA (~3 MDa) must be via an active transport mechanism. Further 
research into whether the dissociated polymer enhanced this active transport into the 
nucleus could see vast improvements in non-viral vectors for the delivery of genetic 
materials. 
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Chapter 4 - Transient Gene Expression Study using Timed-Release Polymers 
4.1 Abstract 
Transient gene expression (TGE) systems have been used as an alternative method for 
production of high quality recombinant proteins due to its ability to rapidly produce the 
protein of interest within weeks compared to stable gene expression which requires 
months which is required for stable expression. This chapter describes three series of 
novel polymers that have been developed to release DNA in a time-dependent manner 
though a self-catalysed hydrolysis mechanism for use as gene delivery vehicles.  The 
polymers were used for the production two recombinant proteins, GFP and a monoclonal 
antibody (IgG1), in two of the most commonly used cell lines for TGE, Chinese hamster 
ovary (CHOS) and human embryonic kidney (HEK293). Using GFP as a reported gene, 
polymer A-C3 demonstrated the highest transfection efficiency in both CHOS and HEK293 
cells with over 50% of cells positive for gene expression for CHOS and over 95% for 
HEK293 cells. Two different approaches to monoclonal antibodies production was tested, 
with the first approach using one plasmid that encodes for both the heavy and light chains 
while for the second, co-transfections are performed using two plasmids, each encoding 
for either the heavy chain or the light Each approach has its own advantages and 
disadvantages. Our results show that the A-C3 polymer was able to achieve higher mAb 
titres using the first approach with a mAb titre of 25 mg/L in HEK293 cells, which was 
comparable to the commercial transfection agent, PEI Max.  
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4.2 Introduction  
Mammalian cells are currently the main hosts for the production of recombinant proteins, 
such as monoclonal antibodies.1 Expression of recombinant proteins usually occurs in 
mammalian cells due to their ability to perform post-translation modifications to produce 
complex proteins that are biologically active in humans.2 The production of these 
recombinant proteins typically occurs in stable cell lines, which can be expensive and time 
consuming (typically 6-12 months). An alternative method for the production of 
recombinant proteins is transient gene expression (TGE). This method can rapidly produce 
high quality proteins within weeks. The advantage of this method is that biopharmaceutical 
companies can screen multiple potential drug candidates in a very short period. 
 
Several mammalian cell lines are commonly used for the production of recombinant 
proteins via TGE.3 Chinese hamster ovary (CHO) and human embryonic kidney (HEK293) 
cells are predominant cell lines used with TGE.4 These cell lines are easily transfected, 
able to grow in suspension and have been used for the production of recombinant proteins 
that have already gained regulatory approval.5 High yields of recombinant mAb have been 
achieved with 1 g/L in HEK293-EBNA cells and 2 g/L in CHO-EBNA-GS cells.6 However, 
recombinant protein yields obtained from TGE is typically lower than what can be achieved 
in stable cell lines.7 To improve yields, efforts are often directed towards optimizing key 
parameters for TGE, including host cell lines, vector systems, cell culture and 
bioprocessing conditions, as well as gene delivery agents.6a, 8 
 
The delivery of the gene of interest is critical for TGE with most methods relying on 
chemical-based delivery mechanisms. Chemical transfection agents used for the delivery 
of DNA into mammalian cells include calcium phosphate9, cationic lipids10 and cationic 
polymers.11 The cationic polymer, polyethylenimine (PEI) is most commonly used as it is 
highly efficient, easy to use and cheap.12 PEI is able to efficiently bind and condense 
plasmid DNA (pDNA) to form a positively charged polyplex with a diameter of ~120 nm 
and a zeta potential of + 35.2 mV. Entry of the polyplex is thought to occur via 
endocytosis13 with escape from the resulting endosome and release into the cytosol 
thought to occur via the proton sponge effect.11a, 14 Once in the cytosol, the polyplex must 
then transport the DNA to the nucleus for transcription of the gene of interest to occur. The 
process of nuclear translocation is not well characterised.15  
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One of the main requirements associated with TGE is that the amount of plasmid DNA 
(pDNA) delivered to the nucleus for protein production to occur needs to be high over the 
transfection period. This is compromised through ineffective delivery to the nucleus and 
further dilution of nuclear-associated pDNA in the daughter cells during cell division. 
Furthermore, the rate of pDNA localisation in the nucleus is key; with various strategies 
employed to increase nuclear localisation of pDNA that include using nuclear localising 
signals or DNA nuclear targeting sequences.16 To combat the issue of pDNA dilution 
during cell division, episomal-based expression systems have been used to maintain or 
even increase plasmid copy numbers. Cells expressing Epstein-Barr virus nuclear antigen 
1 (EBNA-1) have been used in combination with pDNA containing the origin of replication, 
OriP, to enhance transient gene expression.17 In particular a system that is currently used 
in our laboratory is the Epi-CHO system, which has shown to increase and prolong 
expression of recombinant proteins compared to non-episomal systems.8b Several other 
groups have also used these genetically engineered systems and have shown improved 
recombinant proteins expression.8b, 18 
 
In this chapter, three series of novel polymers A-B, A-C and A-D19 (see scheme 4-1A), that 
have been shown to have different release profiles of pDNA (Chapter 2 of reference20), 
were evaluated to determine if the timed-release of pDNA could prolong the lifespan of 
pDNA within the cell and nucleus with measureable effect on mAb expression. The novel 
polymers have been shown to have similar physical attributes in terms of size (~100-200 
nm) and charge (~20-40 mV) as PEI when complexed to pDNA, as well as have 
endosome escape capabilities (see Chapter 2 or reference20). Endosome escape and 
delivery of DNA to the nucleus of the cells are considered the two major barriers to 
successful transfection. The novel polymers used in this chapter have been shown to 
overcome these barriers in HEK293 cells through the high expression levels of GFP, a 
reporter gene. These abilities as well as the ability of timed-released of pDNA from the 
PDMAEA polymer irrespective of environmental conditions will be assessed through the 
production of a mAb over an 8 day expression study. The polymers were first assessed for 
their ability to transfect CHOS cells, a dominate cell line for TGE systems, using pEGFP 
before mAb expression studies were performed. The production of mAb can occur through 
two different approaches (see Scheme 4-1B). Both approaches were tested and the best 
approached was determined by highest titre using the most efficient polymer (A-C3). TGE 
monoclonal antibody studies were performed in both CHOS and HEK293 cell lines.  
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Scheme 4-1: (A) Chemical structures and number of repeating units of P(DMAEA-
b-ImPAA) (A-B1, A-B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-
C3), and P(DMAEA-b-(DMA-co-BA)) (A-D1, A-D2 and A-D3). (B) Two approaches 
to monoclonal antibody production. Approach 1, both the heavy and light chains are 
encoded on the same plasmid. Approach 2, one plasmid encodes for the heavy 
chain only and the other plasmid for the light chain only.  
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4.3 Materials and Methods 
4.3.1 Synthesis of Novel Nanoparticle Polymers 
Information regarding the synthesis of P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) polymers can be found in the reference.19 
 
4.3.2 Transfection Studies 
Transfection experiments and chloroquine studies were performed as outlined in Chapter 
2 or reference20 with the following exception, cell density on the day of transfection for 
CHOS cells was 3x106 cells/mL. PEI Max (Polysciences) complexes were prepared at 1/4 
(w/w, polymer/pDNA). Each component was diluted separating in OptiPro SFM (Life 
Technologies) and incubated at room temperature for one min, mixed and left for a further 
20 min before addition to cells. Transfected cultures were fed 4 h post-transfection with an 
equal volume of CD CHO (Life Technologies) supplemented with 8 mM GlutaMax (Life 
Technologies) and 0.4% ACA (v/v) (Life Technologies). Transfection efficiency was 
measured 48 h post-transfection via the FACSAria II (BD, San Jose, CA). Transfection 
efficiency is defined as the number of fluorescing cells in the transfected population. Ten 
thousand events were measured per sample. Cell density and viability were measured 
using an automated trypan blue exclusion assay using the Cedex HiRes Cell Counter 
(Innovatis AG, Bielefield, Germany) or Countess® Automated Cell Counter (Life 
Technologies).  
 
4.3.3 Confocal Microscopy 
CHOS cells and polyplexes were prepared as above except the pDNA was labelled 
with Cy5 using the Label-IT kit (Mirus Bio, Madison WI). At 4 h post-transfection 
wells were washed with PBS and then with 0.5 M Glycine pH 2.2 in PBS. Cells were 
then fixed with 4% (w/v) paraformaldehyde in PBS for 20 min at RT followed by 3 x 
1 min washes with PBS. Cells were mounted on glass sides with VECTASHIELD 
HardSet Mounting Medium with DAPI (Vector Laboratories) and coverslip place 
over top. Slides were left overnight at 4 °C and visualised under confocal 
microscope LSM 710 (ZEISS, Goettingen, Germany). Z-Stacking experiments were 
performed to determine internalisation of the pDNA.  
 
 
 72 
 
4.3.4 Transient Gene Expression Studies 
Cell density on the day of transfection for CHOS cells was 3x106 cells/mL and 
HEK293 cells was 2x106 cells/mL. Transfections were performed in either 5 mL in 
TPP tubes or 10 mL in 125 mL flasks. Cells were transfected with 2 µg DNA per mL 
of culture. PEI and novel polymers complexes were formed as above. Freestyle 
Max (Life Technologies) was prepared according to the manufactures protocol. For 
transfections using the approach 1 (one pDNA method), co-transfections was 
performed using pIgG1/pEFGP at a ratio of 95/5. For transfections using approach 
2 (two pDNA method), co-transfections were performed using pIgG HC/pIgG LC at 
a ratio 50/50.  Cells were fed 4 h post-transfection with equal volume of CD CHO 
supplemented with 8mM GlutaMax, 7.5% CHO CD Efficient Feed A (Life 
Technologies), 7.5% CHO CD Efficient Feed B (Life Technologies), and 0.4% ACA 
(v/v). or Freestyle 293 supplemented  with 7.5% CHO CD Efficient Feed A, 7.5% 
CHO CD Efficient Feed B, and 0.4% ACA (v/v). On day 2 transfected cultures were 
moved to a 32 °C incubator. Transfection efficiency was determined on day 2 via 
flow cytometry with ten thousand events measured per sample. Cell density and 
viability were measured using an automated trypan blue exclusion assay using the 
Countess® Automated Cell Counter (Life Technologies) on days 2, 4, 6 and 8. The 
concentration of the mAb (IgG1) yields were determined in culture supernatants on 
days 2, 4, 6 and 8 by enzyme-linked immunosorbent assay (ELISA).21  
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4.4 Results and Discussion 
4.4.1 Internalisation, Endosomal Escape and Optimization of Polymer/DNA 
Complexes for Efficient Gene Expression 
The A-B, A-C and A-D polymer series (see Scheme 4-1A) when complexed to pDNA have 
previously been shown to have similar physical characteristics as PEI complexes (an 
efficient transfection agent) in both size and charge (Chapter 2 or reference20). The novel 
polymer complexes have also been shown to transfect HEK293 cells (using pEGFP) with 
varying efficiencies and with the optimum N/P ratio (i.e. the molar ratio of nitrogen atoms 
on the polymer to the phosphate atoms on the DNA backbone) established in Chapter 2 
(or reference20). Similar experiments were performed here with CHOS cells to establish 
the optimum N/P ratio with minimal cellular toxicity. As mentioned in Chapter 2, cellular 
toxicity of the polymers was considered to be an issue when the cell viability dropped 
below 90%. A range of N/P ratios (5-30) were tested for each polymer and transfection 
efficiency was determined by flow cytometry. Transfection efficiency was measured as the 
percentage of cells expressing GFP 48 h post-transfection. 
 
Before optimization experiments were performed in CHOS cells, the ability of the novel 
polymers to internalised pDNA and escape the endosome in this cell line was tested. To 
visualise the uptake of polyplexes within the cell, Cy5-labelled pDNA was used. Images 
obtained from confocal microscopy showed the cell nucleus in blue and pDNA in red 
(Figure 4-1). Several slices were taken to determine that the pDNA was inside the cell 
(Appendix C Figure C4-1). The red (Cy5-label pDNA) areas within the cells indicated that 
the polymers A-B3, A-C3 and A-D3 were able to cross the cell membrane and deliver the 
pDNA within the cell. 
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Figure 4-1: Fixed-cell confocal microscopy 4 h post-transfection in CHOS cells showing 
internalisation of Cy5-pDNA complexes of P(DMAEA-b-ImPAA) (A-B3), P(DMAEA-b-
(ImPAA-co-BA)) (A-C3), and  P(DMAEA-b-(DMA-co-BA)) (A-D3). Cells were stained with 
DAPI to visualise the nucleus (blue). Slice 4 from Z-stacking shown, see Appendix C 
Figure C4-1 for all slices. 
 
Internalisation of pDNA does not necessary translate to successful transfection in terms of 
protein expression. Once inside the cell, the polyplexes must escape the endosome; this is 
considered one of the major bottlenecks in successful transfection. Previous results 
showed that in HEK293 cells pre-treated with chloroquine (a lysosomotropic agent that 
causes endosomes to swell and rupture) that the different polymers (used here) when 
transfected at different N/P ratios were able to escape the endosomes to varying degrees 
(Chapter 2 or reference20). These results showed that polymers within the A-C series with 
the combination of both ImPAA and BA monomers in second bock were found to escape 
the endosome with the highest efficiency based on GFP expression. This chloroquine 
experiment was repeated in CHOS. The novel polymers ability to escape the endosomes 
and then facilitate the nuclear entry of pDNA in CHOS cells treated with and without 
chloroquine was determined by flow cytometry measuring the percentage of cells 
expressing GFP 48 h post-transfection. CHOS cells did not exhibit any toxic effects form 
the addition of chloroquine as cell viability remained similar between treated and non-
treated cells (Figure 4-2B, D and F). The A-B series were still unable to efficiently transfect 
CHOS cells in the presence of chloroquine (Figure 4-2A). As with the HEK293 cells, it was 
observed that the polymers from the A-C series, in particular polymers A-C2 and A-C3, 
were efficient at endosomal escape in CHOS cells as there was little difference in 
transfection efficiency between cells treated with and without chloroquine (Figure 4-2C).  
Finally, the transfection efficiencies did not vary with the A-D series when untreated cells 
were compared to chloroquine treated cells (Figure 4-2E). As the transfection efficiency 
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was low for CHOS cells transfected with the A-D series it was difficult to determine if the A-
D series were efficient at endosomal escape and low transfection efficiencies were due to 
other factors. Generally speaking, there were no noteworthy improvements in transfection 
efficiency with our polymers when CHOS cells were treated with chloroquine when 
compared to non-treated cells, suggesting that endosomal escape was not a limiting factor 
for transfection in CHOS cells. However, transfection is a complex process and it would be 
expected that there are a number of other key attributes involved in TGE such as pDNA 
concentration or optimal N/P ratio used in transfections.  
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Figure 4-2: Endosomal escape assays for P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) at various N/P ratios in CHOS cells pre-treated with and without 100 
µM chloroquine. Results measured 48 h post-transfection. (A), (C) and (E) transfection 
efficiency (B), (D) and (F) cell viability. Data reported as the mean ± standard error of the 
mean of two replicates.  N/P ratios are in parenthesis. 
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In an attempt to improve transfection efficiency of the novel polymer series in CHOS cells, 
optimization in regards to N/P ratios were performed over the range of 5-30. The results 
showed that for CHOS cells transfected with A-B series polymers at the highest N/P ratios 
tested (30) little to no GFP expression occurred (Figure 4-3A and B). For the A-C series 
little GFP expression was observed for cells transfected with A-C1 but for polymers A-C2 
and A-C3 expression of GFP was observed (Figure 4-3C and D).The optimal N/P ratio 
determined was 20 for both the A-C2 and A-C3 polymers as this resulted in the highest 
level of transfection efficiency (up to 50%) with minimal cell death. Finally, the A-D series 
demonstrated higher transfection efficiency at the higher N/P ratios tested, although this 
also resulted in increased cellular toxicity, resulting in an optimum N/P ratio of 10 (Figure 
4-3E and F). 
 
Transfections using the novel polymers exhibited different optimum N/P ratios depending 
on which cell line was transfected, either CHOS or HEK293, both in terms of transfection 
efficiency and cellular toxicity. The transfection efficiency measured by GFP expression 
was also different between the two cell lines using the same transfection agent. Even 
though the expression levels were different between the two cell lines, there was a similar 
trend between the series of polymers and which polymer was able to achieve the highest 
level of transection efficiency. Polymer A-C3 was the best performing polymer regardless 
of cell line transfected with an optimum N/P ratio of 20 for CHOS cells and N/P 5 for 
HEK293 cells. The transfection efficiency using pEGFP in CHOS cells was 53% while in 
HEK293 cells transfection efficiency was almost double at 95%. Differences in transfection 
efficiency using the same transfection agents in different mammalian cell lines have been 
reported in the literature. A report from Patnaik et al22 comparing a small library of PEI-PaP 
nanoparticles for their efficiency to deliver pDNA into various mammalian cells with GFP 
as a reported gene showed that GFP fluorescence intensity varied between the cell lines 
tested using the same transfection agent. Limited data has been reported on the reasons 
why transfection efficiency differs between different cell lines but reasons could include 
difference in cell physiology, efficiency of gene transcription and translation, post-
translation processes and modifications, and cell culture medium.8d 
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Figure 4-3. Transfection efficiency and cell viability of P(DMAEA-b-ImPAA) (A-B1, A-B2 
and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and  P(DMAEA-b-(DMA-
co-BA)) (A-D1, A-D2 and A-D3) at various N/P ratios in CHOS cells 48 h post-transfection. 
(A), (C), and (E) Cell density and (B), (D) and (F) cell viability. Data reported as the mean 
± standard error of the mean of two replicates. N/P ratios are in parenthesis. 
4.4.2 Establishing a Monitoring System for Monoclonal Antibody Production 
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The polymers have shown to be able to facilitate the transport of pEGFP into CHOS and 
HEK293cells as seen by the production of GFP, which is a relatively small recombinant 
protein (27 kDa). A common recombinant protein produced in mammalian cells is the 
larger (150 kDa) mAb. mAb consists of two heavy chains (HCs) and two light chains (LCs) 
joined by disulphide bonds.23 To produce a mAb by TGE, two approaches can be taken 
(see Scheme 4-1B): approach 1 cells are transfected using one pDNA that encodes for 
both HC and LC, and approach 2 cells are transfected using a combination of two pDNA 
encoding for either the HC or the LC.24 Each approach has its own benefits; by using only 
one plasmid to encode for both HC and LC genes, equal amounts of heavy and light chain 
peptides may be produced within the cell increasing the chances of successful folding and 
secretion of the antibody, while using two plasmids the ratio of HC to LC genes can be 
controlled and changed to suit the mAb being produced.24b, 25 Schlatter et al suggests that 
for the production of mAb the optimal HC to LC gene ratio differs for transient and stable 
expression systems with the different possibly caused by increased intracellular HC and 
LC peptide abundance in the endoplasmic reticulum of stable cells.25 One of the other 
differences between the two approaches is the size and copy number of pDNA transfected 
into the cell. Generally, plasmids encoding for both the HC and LC genes are larger than 
plasmids encoding for either the HC or LC separately. The difference in size of the 
plasmids may affect transfection efficiency due to copy number within the cell or may 
impact on the movement of the plasmid through the cytosol and nuclear entry. To 
determine the best method for the novel polymers, both approaches were tested in 
HEK293 cells using the optimum conditions for polymer A-C3, the best performing polymer 
in both CHOS and HEK293 cell lines as determined by transfections using pEGFP. mAb 
titres were compared directly to two commercial transfection agents, PEI Max and 
Freestyle Max.      
 
Approach 1 uses a single plasmid (pIgG1, 9.7 kbp) which encodes for both the HC and 
LC. This plasmid does not encode for a fluorescent protein; therefore, to measure the 
transfection efficiency pEGFP was co-transfected at 5% of the total pDNA used. Previous 
work by Codamo et al have demonstrated that co-transfections using 2.5-5% pEGFP does 
not have a negative effect of mAB yields when compared to transfectants without 
pEGFP.26 This percentage was chosen to keep the plasmid copy number of pIgG1 high as 
well as allowing sufficient pEGFP to be transfected to ensure a signal from the expressed 
GFP can be measured.  The second approach, approach 2, utilises two plasmids IgG1 HC 
(9.6 kbp) and IgG1 LC (8.9 kbp) at a ratio of 1:1, each encoding for the HC and GFP, or 
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LC and mCherry (red fluorescent protein), respectively. This dual plasmid approach has 
been used for the identification and selection of high-antibody producing CHO-cell clones 
for used in producing stable cell lines.21 Here, this approach is used to determine the 
efficiency of the transfection process by measuring the level of fluorescence from the 
expression of GFP and mCherry.  For both approaches transfection efficiency was 
determined on day 2 using flow cytometry by measuring the number of cells producing 
either GFP or mCherry, and on days 2 and 4 IgG titre was quantified by ELISA. 
 
Higher transfection efficiency was seen for A-C3 transfected cells using approach 1 
compared to approach 2 (Figure 4-4). Cells transfected with PEI Max showed the highest 
transfection efficiency regardless of which approach was used. Similar levels of 
fluorescence were seen between A-C3 and PEI when cells were transfected using 
approach 1 suggesting similar IgG titres (Figure 4-4 and 4-5). When approach 2 was 
tested, cells transfected with A-C3 and Freestyle Max showed transfection efficiency as 
measured by GFP and mCherry expression to be less than half of that achieved from PEI 
Max (Figure 4-4C and E). Further analysis of the fluorescence intensity (Figure 4-6) 
revealed that the fluorescence units of GFP and mCherry were similar at ~0.35 and 4.5 
x104, respectively, for PEI Max and Freestyle Max while for A-C3 the fluorescence units 
were lower at 0.16 x104 for GFP and 0.9 x104 for mCherry. The transfection efficiency and 
fluorescence units provide a correlation to the level of mAb also being expressed. The low 
level of mCherry expression in cells transfected with A-C3 compared to cells transfection 
with PEI Max and Freestyle Max indicated that low levels of the LC peptide was also being 
produced. It is possible that further optimization is required in terms of the HC to LC 
plasmid ratio for an increased in mAb titre to occur. It has been reported that sufficient 
concentration of LC peptides are critical for high antibody secretion rates.27 The 
differences seen between cells transfected with the three transfection agents in 
transfection efficiency and fluorescence units suggests potential differences in IgG titre 
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Figure 4-4. Transfection efficiency on day 2 in HEK293 cells comparing approach 1 to 
approach 2. (A) and (B) transfection efficiency and fluorescent units for Approach 1 based 
on number of cells expression GFP. (C) transfection efficiency and (D) fluorescent units for 
cells expressing GFP, and (E) transfection efficiency and (F) fluorescent units for cell 
expressing mCherry for approach 2. Data reported as the mean ± standard error of the 
mean of two replicates. PEI Max polyplexes were formed at polymer/DNA ratio of 4/1 
(w/w),   Freestyle Max polyplexes formed at polymer/DNA ratio of 1/1 (v/w), and A-C3 
polyplexes formed at N/P ratio of 5/1.  
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Figure 4-5: Transient expression of GFP and mCherry in HEK293 cells transfected using 
approach 1. Expression was measured 48 h post-transfection. Signal to the right of the 
vertical bar indicate positive signal for GFP expression. 
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Figure 4-6: Transient expression of GFP and mCherry in HEK293 cells transfected using 
approach 2. Expression was measured 48 h post-transfection. (A) Signal to the right of the 
vertical bar indicate positive signal for either GFP or mCherry expression. (B) 4-quadant 
plot for two-colour system. Signal in Q3 illustrates cells expressing both GFP and 
mCherry. 
 
IgG titre was quantified by ELISA on days 2 and 4 (Figure 4-7). Cells transfected with the 
A-C3 using approach 1 were able to generate higher IgG titres when compared to 
approach 2 with IgG titres on day 4 of 18.6 mg/L and 5.6 mg/L respectively. Cultures 
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transfected with PEI Max were able to produce higher IgG titres regardless of which 
approached used with the highest IgG titre of 27.5 mg/L achieved via approach 1. 
Freestyle Max facilitated higher IgG titre using approach 2 with one third more IgG 
produced compared to approach 1. It has been reported that several parameters can 
affect transfection efficiencies such as plasmid size, the ratio of plasmids containing the 
HC or LC as well as the amount of pDNA used.25, 28 There were no major differences seen 
in cell growth and viability for any of the transfection agents between the two methods 
(Appendix C Figure C4-2). 
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Figure 4-7: Comparison of IgG titre in HEK293 cells transfected using either approach 1 
or approach 2. IgG titres quantified by ELISA from culture supernatants on day 2 and 4. 
(A) Approach 1 and (B) Approach 2. Data reported as the mean ± standard error of the 
mean of two replicates. PEI Max polyplexes were formed at polymer/DNA ratio of 4/1 
(w/w),   Freestyle Max polyplexes formed at polymer/DNA ratio of 1/1 (v/w), and A-C3 
polyplexes formed at N/P ratio of 5/1.  
 
4.4.3 Transient Gene Expression Study 
Based on the results from section 4.4.2 it was decided to that TGE studies using the three 
series of polymers will be performed using approach 1, which is the single pDNA method. 
Transfections were performed using the optimum N/P ratios established in this chapter for 
CHOS cells and the optimum N/P ratio established in Chapter 2 or reference20 for HEK293 
cells. Transfection efficiency was measured 2 days post-transfection with the IgG titre 
measured on days 2, 4, 6 and 8.  
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The transfection efficiency observed in CHOS cells co-transfected with pEGFP was less 
than 5% for the three series of novel polymers with only cells transfected with polymer A-
C2 producing a measurable amount of IgG (Figures 4-8 and 4-9). Cell growth and viability 
was also measured and found no major differences between cultures transfected with 
novel polymers and untransfected cultures (Appendix C Figure C4-3). PEI Max was able to 
achieve transfection efficiency greater than 40% as measured by GFP expression 2 days 
post-transfection and after 8 days the IgG titre was greater than 30 mg/L. As transfection 
using PEI Max was successful in CHOS cells it is reasonable to suggest that the three 
series of novel polymers are unable to transfect CHOS cells successfully using the larger 
plasmid pIgG1. 
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Figure 4-8: Transfection efficiency on day 2 using approach 1 for P(DMAEA-b-ImPAA) (A-
B1, A-B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and 
P(DMAEA-b-(DMA-co-BA)) (A-D1, A-D2 and A-D3) in CHOS cells. Transfection efficiency 
is measured by the number of cells expressing GFP. Data reported as the mean ± 
standard error of the mean of two replicates. N/P ratios are in parenthesis. 
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Figure 4-9: IgG titre using approach 1 for P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) in CHOS cells. IgG titres quantified by ELISA from culture 
supernatants on day 2, 4, 6 and 8. Data reported as the mean ± standard error of the 
mean of two replicates. N/P ratios are in parenthesis. 
 
For HEK293 cells the transfection efficiency was between 10-42% for all transfection 
agents tested, with PEI Max, Freestyle Max and A-C3 showing the highest number of cells 
expressing GFP (Figure 4-10). This trend was mirrored with the IgG production with 
cultures transfected with PEI Max, Freestyle Max and A-C3 exhibiting the highest IgG 
titres (Figure 4-11). On day 4 the IgG titre was similar between cultures transfected with 
PEI Max, Freestyle Max and A-C3 at ~12 mg/L. By day 8 cultures transfected with PEI 
Max and Freestyle Max had slightly higher IgG titres compared to cultures transfected with 
A-C3 but the titres are still comparable at 30-32 mg/L for PEI Max and Freestyle Max and 
25 mg/L for A-C3. Cellular viability was also measured and it was found that cells 
transfected with A-C3 were the only cultures that displayed a substantial decrease in cell 
viability reducing to 50% by day 8 (Appendix C Figure C4-4). For the other novel polymers 
tested the IgG titres were between 5-10 mg/L after 8 days. 
The three polymer series have shown to release pDNA at varying times with polymers 
series A-B and A-D releasing sooner than A-C series polymers (Chapter 2 or reference20). 
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In particular, polymer A-C3 has the longest release time with pDNA being partially 
released after 48 h and full release not until after 168 h. This delay in release may be the 
reason why the A-C3 polymers are able to achieve a high level of transfection efficiency in 
both the production of GFP and IgG. Results from Chapter 2 also determined that polymer 
A-C3 provided the best protection against DNase I suggesting that having a timed-
released ability may have advantages in providing efficient protection against nucleases 
found within the cell. The decrease in cell viability seen in cultures transfected with A-C3 
and not seen in cultures transfected with PEI Max and Freestyle Max is probably a leading 
factor of why IgG titres in cultures transfected with A-C3 were not higher than those in 
cultures transfected with PEI Max and Freestyle Max. Cellular toxicity may be caused by 
accumulation of polymer within the cell or pDNA. The A-C3 polymer is able to degrade into 
non-toxic anionic polymers but the overall impact of these anionic polymers on the 
intracellular environment of a mammalian cell is unknown. Results from Chapter 3 show 
that by 48 hours post-transfection nuclei of cells transfected with A-C3 displayed 5 times 
the amount of pDNA compared to nuclei transfected with PEI Max. This shows that A-C3 
is efficient in the delivery of pDNA to the nucleus but increased concentration of pDNA 
within the nucleus may be having a negative effect not only on cell viability but also on 
transcription. High cell viability can be critical to achieving high mAb titres. Several studies 
into reducing toxicity and increasing yields have investigated media additives, 
hypothermia, and transfecting at higher cell densities.18c, 29 . 
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Figure 4-10: Transfection efficiency on day 2 using approach 1 for P(DMAEA-b-ImPAA) 
(A-B1, A-B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and 
P(DMAEA-b-(DMA-co-BA)) (A-D1, A-D2 and A-D3) in HEK293 cells. Transfection 
efficiency is measured by the number of cells expressing GFP. Data reported as the mean 
± standard error of the mean of two replicates. N/P ratios are in parenthesis. 
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Figure 4-11: IgG titre using approach 1 for P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) in HEK293 cells. IgG titres quantified by ELISA from culture 
supernatants on day 2, 4, 6 and 8. Data reported as the mean ± standard error of the 
mean of two replicates. N/P ratios are in parenthesis. 
 
4.5 Conclusion 
This work has highlighted that different mammalian cell lines can respond differently to the 
same transfection agent. Furthermore, the efficiency of transfection can be dependent on 
the size of the pDNA used with smaller plasmids (5 kbp) appearing to be more readily 
transfected than larger plasmids (10 kbp). This is possibly due to increased number of 
copies of the smaller plasmid inside the cells compared to the larger plasmid when the 
same concentration of DNA is used or that smaller plasmids are able to transverse the 
cytosol and gain entry in the nucleus more readily than larger plasmids.  Polymers from 
the A-C series in HEK293 cells were able to achieve transfection efficiencies of 60-95% for 
straight pEGFP transfection, interestingly for transfections using pIgG1 only A-C3 was able 
to achieve similar mAb titres to PEI Max and Freestyle Max. It is believed that the high 
level of transfection efficiency achieved by polymer A-C3 was due to its ability to strongly 
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bind and protect pDNA, its endosome escape properties as well as its timed-release 
mechanisms (see Chapter 2). This can be an advantageous for TGE as release of pDNA 
starts to occur from 24-48 h after complexing to full release after 168 h, possibility resulting 
in the copy number of pDNA within the cell and more importantly the nucleus being 
maintained, with the consequential effect of extended expression of mAb (or other 
recombinant proteins). The reduction of cellular toxicity in cultures transfected with A-C3 
may be achieved through further optimization of the transfection process, such as 
increasing cell density to minimise pDNA concentrations within each cell or by reducing 
the concentration of pDNA or polymer transfected. If these toxic effects can be reduced or 
even eliminated than polymer A-C3 has the potential to be an efficient timed-released 
transfection agent that is not only able to facilitate both the delivery of small (5 kbp) and 
large (10 kbp) plasmids into mammalian cells for the production of recombinant proteins 
for transient gene expression but also able to release pDNA within the cell over a period of 
time to allow for extended gene expression.  
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Chapter 5 – Final Conclusion 
 
Recombinant proteins can be rapidly produced in mammalian cells by transient gene 
expression systems. These proteins have a wide utility, ranging from biological studies (i.e. 
structure and function) to therapeutic purposes (i.e. biopharmaceuticals and gene 
therapy). Successful transient gene expression requires that the delivery vector strongly 
bind to pDNA and facilitate its entry into the cell, be able to escape the endosome, protect 
and transport pDNA through the cytosol, and finally deliver the pDNA into the nucleus 
where gene expression can occur. The efficiency of this process needs to balance minimal 
cell toxicity with maximum gene expression. The pathways involved in successful 
transfection are not fully understood, and it is believed that the two major bottlenecks in 
this process are endosome escape and nuclear entry.   
 
Novel polymers were synthesized using 'living' radical polymerization for use as gene 
delivery vehicles for the production of recombinant proteins, as well as to investigate and 
define the pathways involved in successful transfection. By using 'living' radical 
polymerization techniques (e.g. SET-LRP and RAFT), polymers can be synthesized with 
defined architecture and molecular weight. Three diblock copolymer series were created 
with PDMAEA as the first block in each of the series, and a second block consisting of N-
(3-(1H-imidazol-1-yl)propyl) acrylamide (ImPAA) or butyl acrylate (BA) monomers, or a 
combination of both. The second block of the copolymers was designed to act in a similar 
way to the influenza virus in its ability to escape the endosome. Within each series the 
number of PDMAEA units was kept constant and the number of units for the second 
block/blocks increasing to create three different molecular weight polymers for each series. 
 
The polymers’ ability to bind, protect and release the pDNA was tested.  All three series of 
polymers were found to be able to strongly bind to pDNA and form polyplexes with 
diameters in the range of 100-200 nm. Protection against DNase I showed that all the 
polymers were able to protect the pDNA to varying degrees, with polymer A-C3 providing 
the best protection. Release of the pDNA is presumed essential for transcription to occur. 
The first block, PDMAEA, is able to self-degrade irrespective of molecular weight and the 
pH of the environment through a self-catalysed hydrolysis mechanism, to a negatively 
charged and non-toxic poly(acrylic acid). The three series of polymers had different 
release rates of pDNA due to the different copolymer compositions.  The A-B series 
polymers had the fastest release of pDNA with release starting from 24 h after 
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complexation, while polymers A-C2 and A-C3 were the slowest, with partial release at 48 h 
and complete release after 168 h.  
 
The results show that the polymers can bind, protect and release pDNA in a timed-
dependent manner. The next step was to determine if these polymers were able to 
overcome the two major barriers for successful transfection; endosome escape and 
nuclear entry. By using a reporter gene, GFP, we found that in HEK293 cells all polymers 
were able to successfully mediate transfection with different efficiencies, while in CHOS 
cells GFP expression was only seen in cells transfected with the A-C and A-D series 
polymers. The A-C series, which contains the combination of the two polymers ImPAA and 
BA, was able to achieve the highest level of transfection efficiency in both cells lines 
tested. Through chloroquine studies, we found that the combination of the two polymers 
(ImPAA and BA) work together to successfully escape the endosome, while either polymer 
alone was unable to promote efficient endosome escape. The differences seen between 
the two cell lines, in regards to transfection efficiencies, are most likely due to differences 
in cell physiology, efficiency of gene transcription and translation and post-translation 
processes between CHO and HEK cells. 
 
To determine the pathways involved in the uptake of pDNA/polymer complexes in HEK293 
cells, both inside the cell and nucleus, a number of chemicals that inhibit either 
endocytosis pathways or nuclear entry were used.  The results show that polymer A-C3 
preferred the clathrin-mediated endocytosis pathway.  The results also show that nuclear 
entry is not via mitosis when the nuclear membrane is temporally disintegrated, but 
through the nuclear pores with the possibility of active transport, due to the size of pDNA. 
It is thought that nuclear entry is mediated through hydrophobic interactions between the 
polymer (A-C3 polymer contains butyl acrylate units) and the hydrophobic FG-nups on the 
nuclear pore, with disassociation between the polymer/pDNA occurring on the nuclear 
membrane or in the nuclear pore. Comparing the amount of pDNA within the nuclei of 
transfected cells as determined by qPCR 24 h post-transfection, it was found that cells 
transfected with A-C3 had 7 times more pDNA compared to cells transfected with PEI 
Max.  
 
The production of a large recombinant protein such as a monoclonal antibody was the final 
step in gauging the ability of the polymers to be used in transient gene expression. 
Polymer A-C3 has shown the ability to produce a similar yield of a monoclonal antibody 
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IgG, to two of the commercially available agents PEI Max and Freestyle Max, 4 days post-
transfection. After this time toxicity becomes an issue, resulting in lower yields than 
commercial standards.  
 
In conclusion, the strategies employed in this thesis to engineer a gene delivery vehicle 
has resulted in an efficient cationic polymer, with both endosome escape properties and a 
timed-released mechanism, to successfully transport pDNA into the nucleus of cells and 
produce small and large recombinant proteins. Further engineering to reduce cellular 
toxicity could see polymer A-C3 rival commercially available transfection agents and 
become a viable alternative for use in transient gene expression systems.   
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Appendix A 
 
 
 
Figure A2-1: Agarose gel retardation assay of P(DMAEA) (A), P(DMAEA-b-(ImPAA) (A-
B1, A-B2 and A-B3), and P(DMAEA-b-(DMA-co-BA)) (A-D1, A-D2 and A-D3) /pDNA 
complexes. Complexes formed using 1 µg of pDNA at different N/P ratios (0.5-20). 
Complexes incubated at room temperature for 30 min before running on a 1% agarose gel 
at 90 V for 30 min. 
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Table A2-1: Zeta potential of P(DMAEA) (A), P(DMAEA-b-ImPAA) (A-B1, A-B2 and A-B3), 
P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) complexes with pDNA (16 µg) in water at different N/P ratios (5, 25 
and 50). PEI/pDNA complex 4:1 (w/w) 35.2 mV. Zeta potential is an average of three 
measurements.   
 
N/P 
Ratio 
Zeta Potential mV 
A A-B1 A-B2 A-B3 A-C1 A-C2 A-C3 A-D1 A-D2 A-D3 
5 29.5 21.87 24.17 24.30 26.60 31.57 32.67 29.63 38.13 39.80 
25 23.9 22.13 25.70 23.77 36.00 34.27 37.83 33.70 35.43 33.30 
50 7 15.60 18.00 15.37 30.40 28.70 33.83 34.93 30.63 31.20 
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Figure A2-2: Endosomal escape assays for P(DMAEA) (A) at various N/P ratios in 
HEK293 cells pre-treated with and without 100 µM chloroquine 48 h post-transfection. (A) 
Transfection efficiency and (B) cell viability. Data reported as the mean ± standard error of 
the mean of two replicates. N/P ratios are in parenthesis.  
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Figure A2-3: Transfection efficiency and cellular viability of P(DMAEA-b-ImPAA) (A-B1, A-
B2 and A-B3) at various N/P ratios in HEK293 cells 48 h post-transfection. (A) Cell density 
and viability and (B) transfection efficiency.  Data reported as the mean ± standard error of 
the mean of two replicates. N/P ratios are in parenthesis.  
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Figure A2-4: Transfection efficiency and cellular viability of P(DMAEA-b-(ImPAA-co-BA)) 
(A-C1, A-C2 and A-C3) at various N/P ratios in HEK293 cells 48 h post-transfection. (A) 
Cell density and viability and (B) transfection efficiency. Data reported as the mean ± 
standard error of the mean of two replicates. N/P ratios are in parenthesis.  
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Figure A2-5: Transfection efficiency and cellular viability of P(DMAEA-b-(DMA-co-BA)) (A-
D1, A-D2 and A-D3) at various N/P ratios in HEK293 cells 48 h post-transfection. (A) Cell 
density and viability and (B) transfection efficiency. Data reported as the mean ± standard 
error of the mean of two replicates. N/P ratios are in parenthesis. 
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Figure A2-6: Transfection efficiency and cellular viability of P(DMAEA) (A) at various N/P 
ratios in HEK293 cells 48 h post-transfection. (A) Cell density and viability and (B) 
transfection efficiency. Data reported as the mean ± standard error of the mean of two 
replicates. N/P ratios are in parenthesis.  
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Scheme B3-1: General synthesis procedure for Oregon green 488 functionalized A-C3 
copolymer. 
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Figure B3-1: SEC trace of Oregon green 488 conjugated A-C3 copolymer with DMAc as 
eluent and UV-Vis detector at 518 nm. 
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Figure B3-2: Effect of endocytosis inhibitors on cellular density and viability in HEK293 
cells 48 h post-transfection. (A) Chlorpromazine (10 µg/mL), (B) Filipin III (1 µg/mL), (C) 
Dynasore (25 µg/mL), and (D) Amiloride (30 ng/mL). Data reported as the mean ± 
standard error of the mean of two replicates. N/P ratios are in parenthesis. 
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Figure B3-3: Uptake kinetics of labelled PEI-FITC and A-C3-Oregon green / pmCherry 
polyplexes in HEK293 cells over the first 48 h.  (A) Whole cells and extracted nuclei of 
cells transfected with PEI Max. (B) Whole cells and extracted nuclei of cells transfected 
with A-C3. PEI Max polyplexes were formed at polymer/DNA ratio of 4/1 (w/w), and A-C3 
polyplexes formed at N/P ratio of 5/1. Data reported as the mean ± standard error of the 
mean of three replicates. 
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Figure B3-4: Cellular density and viability of labelled PEI-FITC and A-C3-Oregon green / 
pmCherry polyplexes in HEK293 cells 24 and 48 h post-transfection. PEI Max polyplexes 
were formed at polymer/DNA ratio of 4/1 (w/w), and A-C3 polyplexes formed at N/P ratio of 
5/1. Data reported as the mean ± standard error of the mean of three replicates. 
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Figure B3-5: Cellular density and viability of PEI Max and A-C3 / pEGFP polyplexes in 
HEK293 cells treated with and without 50 µg/mL of wheat germ agglutinin 48 h post-
transfection. PEI Max polyplexes were formed at polymer/DNA ratio of 4/1 (w/w), and A-C3 
polyplexes formed at N/P ratio of 5/1.Data reported as the mean ± standard error of the 
mean of two replicates. Data reported as the mean ± standard error of the mean of four 
replicates. 
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Figure C4-1: Fixed-cell confocal microscopy showing Z-stacking 4 h post-transfection in 
CHOS cells showing internalisation of Cy5-pDNA complexes of P(DMAEA-b-ImPAA) (A-
B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C3), and  P(DMAEA-b-(DMA-co-BA)) (A-D3). Cells 
were stained with DAPI to visualise the nucleus (blue).  
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Figure C4-2: Cell Density and viability in HEK293 transfected cultures using approach 1 
and approach 2. (A) Cell density and (B) cell viability. Data reported as the mean ± 
standard error of the mean of two replicates. PEI Max polyplexes were formed at 
polymer/DNA ratio of 4/1 (w/w),   Freestyle Max polyplexes formed at polymer/DNA ratio of 
1/1 (v/w), and A-C3 polyplexes formed at N/P ratio of 5/1.  
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Figure C4-3: Cell density and viability using Approach 1 for P(DMAEA-b-ImPAA) (A-B1, 
A-B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-
(DMA-co-BA)) (A-D1, A-D2 and A-D3) in CHOS cells. After transfection cells were kept at 
37 °C until day 2 where they were moved to a 32 °C incubator. (A) Cell density and (B) cell 
viability. Data reported as the mean ± standard error of the mean of two replicates. N/P 
ratios are in parenthesis. 
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Figure C4-4: Cell density and viability using Approach 1 for P(DMAEA-b-ImPAA) (A-B1, 
A-B2 and A-B3), P(DMAEA-b-(ImPAA-co-BA)) (A-C1, A-C2 and A-C3), and P(DMAEA-b-
(DMA-co-BA)) (A-D1, A-D2 and A-D3) in HEK293 cells. After transfection cells were kept 
at 37 °C until day 2 where they were moved to a 32 °C incubator. (A) Cell density and (B) 
cell viability. Data reported as the mean ± standard error of the mean of two replicates. 
N/P ratios are in parenthesis. 
